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INTRODUCTION
Intent of Revision
The Korean Liver Cancer Study Group (KLCSG)–National 
Cancer Center (NCC) Korea practice guidelines for the 
management of hepatocellular carcinoma (HCC) were first 
announced in 2003 and have been revised twice, first in 
2009 and then in 2014. Since then, many new research 
findings and therapies for HCC have been presented and 
published in Korea and other countries. Many studies have 
been conducted and a substantial body of knowledge has 
been accumulated on diagnosis, staging, and treatment 
specific to Asia that shows different clinical behaviors of 
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HCC from the West, especially in Korea; this has provided 
action plans and measures based on the new research 
findings. Accordingly, in the summer of 2017, the Korean 
Liver Cancer Association (KLCA, formerly KLCSG)–NCC 
Korea Practice Guideline Revision Committee (KPGRC) has 
initiated the revision of the guidelines to develop a new 
recommendation plan that integrates the most up-to-date 
research findings and expert opinions after the release of 
the 2014 guidelines.
Target Population
The primary targets of these new guidelines are 
patients with suspicious or newly diagnosed HCC. The 
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key to treatment according to these guidelines is the 
initial treatment of patients with newly diagnosed HCC; 
however, for the first time we extensively reviewed and 
discussed residual, progressive, or recurrent cancer after 
initial treatment and provided relevant recommendations. 
Moreover, these guidelines can be applied more usefully 
to actual clinical practice by also describing prevention 
methods, surveillance tests, a treatment overview, 
preemptive antiviral treatment of underlying chronic 
hepatitis and management of cancer pain, and an 
assessment of the tumor response after treatment.
Intended Users
These guidelines are intended to provide useful clinical 
information and direction for all clinicians in charge of the 
diagnosis and treatment of HCC in Korea. It also provides 
specific and practical information for medical residents in 
training, specialists, and their instructors.
Developers and Funding Source
The KLCA-NCC KPGRC organized by the consensus of 
the KLCA and NCC consists of hepatologists, oncologists, 
surgeons, radiologists, and radiation oncologists. All required 
funding was provided by the NCC (#1731510-1). Each member 
of the KPGRC collected and analyzed relevant evidence and 
wrote the manuscript. Conflicts of interests among the 
members are summarized in Supplementary Table 1.
Literature Search for Evidence Collection
The 2018 KPGRC (Supplementary Table 2) collected and 
analyzed the Korean and international literature published 
on HCC since the announcement of the 2014 guidelines 
through a PubMed search for revisions of the guidelines 
based on latest updated evidence. Only English and Korean 
literature was searched, and the keywords included HCC 
and other keywords specific to related subtopics. The sub-
topics encompassed a wide range of clinically important 
items such as epidemiology, prevention, diagnosis, staging, 
treatment, and response assessment of HCC.
Systematic Literature Review, Levels of Evidence, 
Grading of Recommendations
Literature collected for evidence was analyzed through 
systematic review, and levels of evidence were classified 
by the revised Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) (Table 1) (1-4). 
The levels of evidence were categorized on the basis of 
the possibility of changes in the assessment through 
further research, and were defined as high (A) with lowest 
possibility, moderate (B) with certain possibility, and low 
(C) with highest possibility. For example, level A evidence 
is similar but not identical to that from one or more 
randomized controlled trials (RCTs). Even if there is no 
possibility of a change in the level of evidence because 
further RCTs are unlikely to be conducted, such evidence 
could be considered level A. In contrast, RCTs that have 
a small population of target patients and need further 
research or are published only in abstracts also have a lower 
level of evidence. The GRADE system was implemented for 
classifying grades of recommendation as strong (1) and 
weak (2), collectively considering not only the level of 
evidence but also the quality, patient-important outcome, 
and socioeconomic aspects of each study. Therefore, each 
recommendation was graded on the basis of the level of 
evidence (A–C) and grades of recommendation (1 or 2) 
as follows: A1, A2, B1, B2, C1, or C2 (Table 1). These 
Table 1. Grading of Recommendations, Assessment, Development and Evaluation
Grade Criteria
Quality of evidence
High (A) Further research is unlikely to change confidence in estimate of clinical effect
Moderate (B) Further research may change confidence in estimate of clinical effect
Low (C) Further research is very likely to impact confidence on estimate of clinical effect
Strength of recommendation
Strong (1)
Factors influencing strength of recommendation included the quality of evidence, presumed 
  patient-important outcomes, and cost
Weak (2)
Variability in preferences and values, or more uncertainty. Recommendation is made with less certainty,
  higher cost or resource consumption
Regarding quality of evidence, we excluded “very low quality (D)” in our guidelines for convenience, which was originally included in 
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system and indicates that any estimate of effect is very 
uncertain. Evidence levels were downgraded if there was only abstract or there was poor quality or inconsistency between studies; levels 
were upgraded if there was large effect size.
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guidelines avoided giving C2 grades as much as possible.
List of the Clinical Questions
The KPGRC selected sub-topics and clinical questions from 
four departments regarding the revision of the guidelines 
(Supplementary Table 3), reviewed the evidence of each 
item, and suggested recommendations through discussion 
with each subcommittee and the KPGRC.
Manuscript Review
Recommendation drafts were made through several 
intradepartmental meetings after the initial meeting of the 
KPGRC and three interdepartmental meetings attended by all 
members of the committee. The drafts were then thoroughly 
reviewed through several online discussions and three 
department head meetings. In addition to the integrity of 
the contents, methodological validity of the manuscript was 
also evaluated on the basis of the Appraisal of Guidelines 
for Research and Evaluation II (AGREE II) (5, 6). The 
complete draft was then reviewed by the advisory board 
and through a public meeting and was modified further at 
the KPGRC department head meeting. The advisory board 
consists of nine clinical specialists in liver cancer. The 
guidelines made through this process were endorsed by the 
open meeting, board of directors of the KLCA, and the NCC 
(Supplementary Table 4).
Release of Guidelines
The revised guidelines were presented at Liver Week on 
June 15, 2018 held jointly by the Korean Association  for 
the Study of the Liver, KLCSG, Korean Association of Hepato-
Biliary-Pancreatic Surgery, and Korean Liver Transplantation 
Society. The Korean version is available on the KLCSG and 
NCC websites (http://livercancer.or.kr and http://ncc.re.kr).
Plan for Updates
The KLCA and NCC Korea will update part or all of these 
guidelines when new test methods, drugs, or treatments 
regarding HCC are developed and new significant research 
findings are made, and thus revision of the guidelines is 
deemed necessary for promoting the national health of Korea. 
The schedule for this plan will be posted when necessary.
Epidemiology
Metrics of Disease Burden from Liver Cancer
The disease burden of a cancer is often expressed as 
cause-specific mortality due to the cancer and incidence 
of the cancer. Of these two indicators, the cause-specific 
mortality rate is used as the most important and fundamental 
measure of disease burden assessment. Mortality due to a 
specific disease and its trend for each country is critical 
for informed priority setting and for prioritizing policy and 
research for new health technologies. Trends in causes 
of death provide an important geographical summary of 
whether society is making progress in reducing the burden 
of premature (and especially avoidable) mortality and where 
renewed efforts are needed (7, 8).
Korea’s cancer mortality rate is reported by the Korean 
Statistical Information Service (KOSIS) as both a crude 
rate and an age-standardized rate (adjusted for the 2005 
mid-year population). In this guideline, Korea refers to 
South Korea. Cancer incidence is reported by the Korea 
Central Cancer Registry (KCCR) as both a crude rate and 
an age-standardized rate (adjusted for the 2000 mid-
year population). There is no significant difference in the 
analysis result according to the standard population that 
is used in the age-standardized rate. However, the crude 
rates and the age-standardized rates may be inconsistent 
with each other. This is especially true when the whole 
population is aging rapidly, as in the case of Korea. The U.S. 
Center for Disease Control and Prevention recommends that 
the decision to use the crude rate or age-standardized rates 
depends on the purpose of the evaluation (https://www.
cdc.gov/cancer/npcr/uscs/technical_notes/stat_methods/
rates.htm). Age-standardized rates ensure that differences 
in incidence or deaths between geographical areas are not 
due to differences in the age distribution of the populations 
being compared. However, crude rates and the absolute 
number of deaths are more helpful in determining disease 
burden and the specific requirements for services for a given 
population.
In this context, this guideline considers that the crude 
death rate (and the absolute number of deaths) is the most 
important indicator of the disease burden from liver cancer 
or HCC. The crude incidence rate, age-standardized death 
rate, and age-standardized incidence rate are considered as 
auxiliary indicators.
Liver Cancer Mortality and Economic Burden
The most important cause of death of Korean people 
is malignant neoplasm, or cancer. According to statistics 
released by the KOSIS, the cancer mortality rate in 2016 
was 153 per 100000 population, ranking first, nearly three 
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times higher than the second-highest cause of mortality, 
which is heart disease at a rate of 58.2 per 100000 
population. In 2016, the mortality rate for liver cancer 
was 21.5 per 100000 population, the second highest 
cancer death rate after the lung cancer mortality rate of 
35.1 per 100000 population. The mortality rate for liver 
cancer among all age groups was second in men (31.5 per 
100000 population) and third in women (11.6 per 100000 
population). However, liver cancer mortality was the 
highest among the economically active working age group, 
who were aged 40 to 59 years old.
The annual economic burden caused by liver cancer in 
Korea was USD 3114 million (about KRW 3.4 trillion) in 
2010, making it the highest among all cancers, and showed 
a large increase on the burden of USD 2065 million (about 
KRW 2.3 trillion) in 2000 (9). In other words, liver cancer 
has the greatest burden of all cancers in Korea.
Trends in Liver Cancer Mortality and Incidence
The crude annual rate of liver cancer mortality has 
increased over the last 30 years, which is why the disease 
burden of liver cancer is increasing. The annual rate of liver 
cancer per 100000 population increased steadily from 16.2 
persons in 1984 to 20.5 persons in 1999 and 22.9 persons 
in 2002, and then remains stable between 21 and 23 up to 
2015 (Fig. 1). The absolute number of annual deaths from 
HCC has also increased by 17.8% over the past 20 years, 
from 9682 in 1999 to 11405 in 2013 (Fig. 2). The crude 
annual incidence of liver cancer has also increased over the 
past two decades. The annual incidence of HCC per 100000 
population has continuously increased from 28.2 in 1999 to 
32.7 in 2010 and remains stable at 31–32 up to 2015.
In contrast to the increase in crude mortality and crude 
incidence of liver cancer, the age-standardized mortality 
and age-standardized incidence of liver cancer have 
declined over the past two decades. The age-standardized 
mortality rate of liver cancer per 100000 people has 
greatly decreased from 24.7 in 1999 to 16.4 in 2014, and 
the age-standardized incidence rate from 33.8 in 1999 to 
19.9 in 2014. The dissociation between crude and age-
standardized rates of liver cancer mortality and incidence 
may be explained by rapidly aging population in Korea. The 
average age and distribution of elderly people in the whole 
Korean population have increased sharply between 1999 
and 2014. The age-standardized rates of liver cancer seem 
to be further lowered because the mean age of the patients 
with liver cancer has increased more than that of the whole 
population.
Summary
In summary, in Korea, the mortality rate of liver cancer 
is the second highest across all age groups, but is highest 
in the economically-active age group, and thus the disease 
burden of liver cancer has been the highest among various 
cancers over the past 20 years. The age-standardized 
mortality and incidence rates of liver cancer appear to be 
declining; however, this is not because of a reduced burden 
of liver cancer, but because of the rapid aging of the entire 
Korean population. Crude rates, incidence rates, and the 
absolute number of patients associated with liver cancer 
mortality are still increasing. These data suggest that liver 
cancer is the most important cancer to overcome in Korea.
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Prevention
Causes and Prevention of HCC
HCC occurs almost exclusively in patients with risk 
factors, such as chronic hepatitis B, chronic hepatitis C, or 
liver cirrhosis. The most important cause of HCC in Korea is 
chronic hepatitis B virus (HBV) infection. According to the 
results of a random selection registry study of the KLCA and 
the KCCR, 62.2% of patients diagnosed with HCC between 
2008 and 2010 were infected with HBV and 10.4% with 
hepatitis C virus (HCV). Unknown causes accounted for the 
remaining 27.4% (10). It is presumed that liver cirrhosis 
caused by alcoholic and/or nonalcoholic fatty liver disease 
would be the main underlying disease for the unknown 
causes. HBV rates are somewhat higher in cohorts of HCC 
patients visiting tertiary hospitals. Because about 90% 
of patients with HCC have cirrhosis or chronic hepatitis B 
at diagnosis, it is difficult to perform radical treatment, 
and the risk of recurrence continues even 5 years or 10 
years after treatment, which worsens the prognosis of the 
patients. According to the National Cancer Registry released 
by the KCCR in 2017, the 5-year survival rate of patients 
with HCC is 33.6% and the 10-year survival rate is as low 
as 20% (11). These data suggest that preventive measures 
against HCC are of utmost importance.
Primary prevention of HCC is to prevent the risk of HCC, 
including vaccination against HBV and abstinence from 
alcohol consumption. Secondary prevention is to reduce the 
risk of developing HCC in patients who already have a risk 
of HCC, including antiviral treatment for HBV and HCV to 
prevent progression of chronic inflammation and fibrosis of 
the liver. Tertiary prevention is to prevent the development 
of new HCC in the remaining liver after curative treatment 
in patients who have already developed HCC (12).
Primary Prevention of HCC
The most important preventive measure for HCC in Korea 
is the universal neonatal vaccination against HBV, since 
most HBV infection is caused by vertical transmission of 
the virus from mother to child in the neonatal period (13). 
HBV vaccination should be given as early as possible within 
24 hours after birth. The World Health Organization (WHO) 
recommends HBV vaccination for all newborns regardless of 
maternal HBV status (14). In addition, adults who do not 
have antibodies to the HBV surface antigen (HBsAg) and 
who have never been exposed to the virus (negative for all 
HBsAg, HBV surface antibody [anti-HBs], and IgG HBV core 
antibody [anti-HBc]) should be vaccinated against HBV 
(15, 16). In particular, people at high risk of HBV infection 
(family members of chronic hepatitis B patients, health 
care workers, travelers traveling to areas with high HBV 
prevalence, injected drug abusers, and people with multiple 
sexual partners, etc.) should also be vaccinated against 
HBV.
No vaccine has yet been developed to prevent HCV 
infection. Because HCV is transmitted almost entirely 
through contaminated blood, infection must be prevented 
by avoiding unsanitary invasive procedures (such as 
multiple use of acupuncture needles, capping, tattooing, or 
needle sharing).
Excessive alcohol intake over an extended time is an 
independent cause of liver cirrhosis and HCC, and further 
increases the risk of liver cirrhosis and HCC in patients with 
preexisting chronic liver disease. In Korea, alcoholic liver 
cirrhosis is the third leading cause of HCC after chronic 
hepatitis B and C. Therefore, efforts should be made to 
lower the risk of developing HCC by limiting excessive 
alcohol consumption.
Metabolic syndrome and fatty liver disease are associated 
with obesity and diabetes mellitus, and are also known to 
increase the incidence of HCC (17, 18). Therefore, efforts 
to reduce obesity and metabolic syndrome are necessary 
to prevent the development of HCC. Statins for treating 
hyperlipidemia have been extensively studied for an 
association with the reduction of HCC risk. Large-scale 
meta-analyses have reported that statin use is associated 
with a reduction in the incidence of HCC by 37% (19); 
however, most of the studies were retrospective analyses, 
and two RCTs did not show a reduction of HCC incidence 
with statin therapy. Therefore, statins do not yet have 
a sufficient evidence to lower the incidence of HCC, and 
caution is needed because the long-term safety of statins is 
not well documented in patients with cirrhosis at high-risk 
of HCC (20). In addition, a study reported that metformin 
reduced HCC development in type 2 diabetes (21), which 
needs further prospective study.
Aspirin and other antiplatelet agents have also been 
suggested to reduce the risk of developing HCC in large 
prospective population-based observational studies (relative 
risk [RR], 0.59; 95% confidence interval [CI], 0.45 to 0.77) 
(22, 23). However, caution is needed in the interpretation 
of the study results because the use of antiplatelet agents 
is generally limited in patients with cirrhosis who are at 
high risk of developing HCC, which might have caused 
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selection bias in studies including low-risk patients in the 
anti-platelet therapy group (24).
Coffee is the only food or drink that has evidence for 
reducing the risk of HCC. In recent meta-analyses and large-
scale cohort studies, coffee consumption significantly 
reduced the risk of developing HCC, regardless of the 
consumption amount, as well as the severity and cause of 
underlying liver disease (25-28).
Secondary Prevention of HCC
Continued high-level viremia in patients with chronic 
hepatitis B or C is an independent risk factor for the 
development of HCC. Therefore, inhibition of HBV or HCV 
proliferation by antiviral therapy is expected to reduce the 
incidence of HCC. For antiviral therapy of chronic hepatitis 
B and chronic hepatitis C, we recommend following the 
clinical practice guidelines of the Korean Association for the 
Study of Liver (KASL) (29, 30).
Oral antiviral agents, such as tenofovir and entecavir, 
are preferred as the first-line treatment for chronic HBV 
infection. There is no RCT to determine whether interferon 
therapy reduces the incidence of HCC in chronic hepatitis B 
patients. Lamivudine, the first oral antiviral agent in patients 
with chronic hepatitis B, has been shown to reduce the 
incidence of HCC in patients with advanced hepatic fibrosis 
in an RCT (32 months follow-up: lamivudine vs. control, 
3.9% vs. 7.4%; p = 0.047) (31). Large-scale observational 
studies have consistently shown that long-term therapy with 
entecavir and tenofovir, potent antiviral agents that have a 
strong inhibitory effect on HBV proliferation, significantly 
reduce the incidence of HCC compared with the untreated 
control group (32-34). However, it is not clear whether 
the effect of tenofovir or entecavir on HCC risk reduction 
is greater than that of lamivudine. It is clear that the risk 
of HCC does not completely disappear even with long-term 
potent antiviral medication (35-38). In conclusion, the 
preventive effect of long-term oral antiviral therapy on HCC 
in patients with chronic hepatitis B has been proved, but is 
not complete (39).
The primary aim of chronic hepatitis C treatment is to 
achieve a sustained virologic response (SVR) that is defined 
as undetectable HCV RNA using polymerase chain reaction 
(PCR) at 12 or 24 weeks after the end of treatment. The 
HCV recurrence rate after an SVR is only about 1% in 
the long term, so it is regarded as a virological cure. The 
achievement of an SVR can prevent progression to cirrhosis 
and the development of HCC. However, in patients with 
preexisting hepatic fibrosis, there is a continuing risk of 
developing HCC even after achieving an SVR (34).
Interferon therapy has been consistently reported to 
reduce the incidence of HCC in chronic hepatitis C patients 
compared with untreated controls. In a meta-analysis of 
20 studies (4700 patients), the HCC risk was significantly 
reduced in the interferon treatment group (RR, 0.43; 95% 
CI, 0.33 to 0.56) and to a greater extent in patients with 
an SVR (RR, 0.35; 95% CI, 0.26 to 0.46) compared with 
those in the control group (40). Another meta-analysis of 
30 studies (approximately 25000 patients) reported a 76% 
reduction in the incidence of HCC in patients with an SVR 
compared with those without an SVR (41). These results 
were consistent regardless of the degree of hepatic fibrosis 
or the presence of cirrhosis.
Direct-acting antivirals (DAAs) against HCV have been 
introduced successively, leading to an SVR achievement rate 
as high as 98% to 100%. In a large-scale retrospective study 
of 22500 patients in U.S. Veterans Health Administration 
Hospitals, the risk of developing HCC was significantly lower 
than that of patients without an SVR with DAA treatment, 
which was a 0.28-fold reduction (42). However, among 
patients with an SVR, those with cirrhosis had a 4.73-fold 
higher risk of developing HCC compared with those without 
cirrhosis. In another retrospective study of 62354 patients 
in the U.S. Veterans Health Administration Hospitals 
database, the incidence of HCC was reduced by 71% when 
an SVR was achieved with DAA therapy (43). In a meta-
analysis comparing the risk of developing HCC between 
DAA treatment and interferon therapy, the incidence and 
recurrence rates of HCC were not different between the two 
treatments after adjusting the follow-up period and patient 
age (44). In summary, although there are limitations of a 
short observation period and retrospective nature in most of 
the studies, the achievement of an SVR with DAA treatment 
was consistently associated with a reduced incidence of 
HCC. However, long-term prospective follow-up studies are 
needed.
Tertiary Prevention of HCC
HCC is associated with a high rate of recurrence even 
after curative treatment; the 5-year recurrence rate is 
as high as 50% to 70%; thus, tertiary prevention is 
very important. Recurrence within 2 years after curative 
treatment is highly likely to be metastasis of the primary 
tumor, and thus adjuvant cytotoxic chemotherapy has been 
tried without proving recurrence reduction or prolongation 
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of survival (34).
There has been no RCT to determine whether antiviral 
treatment could reduce the incidence of HCC after 
hepatectomy in patients with chronic HBV or HCV infection. 
However, many observational studies have reported that oral 
antiviral therapy after curative treatment of HBV-associated 
HCC can significantly reduce recurrence of HCC by up to 
50% (hazard ratio [HR], 0.48) (45). A meta-analysis showed  
that antiviral treatment for HBV after curative treatments 
(i.e., surgical resection, radiofrequency ablation [RFA], and 
percutaneous ethanol injection) reduced the recurrence of HCC 
(55% vs. 58%: odds ratio [OR], 0.59; 95% CI, 0.35 to 0.97; p 
= 0.04), liver-related mortality (0% vs. 8%: OR, 0.13; 95% CI, 
0.02 to 0.69, p = 0.02), and overall mortality (38% vs. 42%: 
OR, 0.27; 95% CI, 0.14 to 0.50; p < 0.001) (46, 47).
In a meta-analysis of interferon therapy after curative 
treatment for HCV-associated HCC that observed 665 
patients for 2 to 7 years, the achievement of an SVR was 
associated with a 74% reduction in the HCC recurrence rate 
and a 60% reduction in the mortality rate (48). In another 
meta-analysis, HCC recurrence was significantly lower in 
the interferon-treated group than in the non-treated group 
after surgical resection (47).
A case series reported that the DAA treatment seems to 
increase the recurrence of HCC. In this study, 58 patients 
who received DAA therapy after treatment for HCV-
associated HCC showed a 27.6% HCC recurrence rate at 
a median of 5.7 months (49). It was suggested that the 
mechanism of high HCC recurrence in the patients would be 
DAA-induced immunologic derangements (50-53). A short-
term Italian study reported that DAA treatment failed to 
reduce the incidence or recurrence of HCC (54). However, in 
a large prospective cohort study of French Agency for AIDS 
and Viral hepatitis Research, after the curative treatment 
of HCC, the recurrence rate was not significantly different 
between the DAA-treated group and the no-treatment 
group; nevertheless, there was a significantly higher HCC 
recurrence rate in the no-treatment group in the presence of 
compensated cirrhosis (55). In the prospective multicenter 
RECIST-HCV cohort study (56), HCC recurred in 19% of 
the DAA-treated patients, which was not significantly 
higher than untreated historical control patients. In a 
small Japanese retrospective study of patients with HCC 
treated with RFA, the recurrence rate of HCC was the lowest 
in patients treated with DAA compared with interferon 
treatment and no treatment (30% vs. 68% vs. 64%, 
respectively), and DAA treatment was not associated with 
recurrence of HCC (57). In another Japanese retrospective 
study of patients who underwent curative treatment of HCC 
(58), the recurrence rate of HCC was significantly higher 
in untreated patients than in those treated with DAA (at 
year 2: 25.0% vs. 46.5%, p = 0.003). In this study, DAA 
treatment reduced the risk of recurrence of HCC by 65%. 
In summary, recurrence of HCC may occur during or after 
treatment with DAA; however, treatment with DAA does 
not appear to increase the recurrence rate of HCC (44, 59). 
Long-term comparative studies are needed to determine the 
relationship between DAA treatment and HCC recurrence.
[Recommendations]
1.  All newborns (A1) and seronegative (negative for all 
of HBsAg, anti-HBs, and anti-HBc) children and adults 
should be vaccinated against HBV (B1) to prevent HCC.
2.  General HCC preventive measures include the following: 
prevention of HBV/HCV transmission (A1); avoidance 
of alcohol abuse; and control of metabolic disorders, 
such as obesity and diabetes (C1).
3.  Antiviral therapy as a secondary prevention of HCC 
may follow the KASL guidelines for the management of 
chronic hepatitis B (A1).
4.  The risk of HCC can be reduced if HBV replication 
is completely suppressed in patients with chronic 
hepatitis B (A1), and if an SVR is achieved by 
interferon therapy (A2) or by DAA therapy (C1) in 
patients with chronic hepatitis C.
5.  After curative treatment of HBV-associated HCC, anti-
HBV therapy should be considered to reduce the risk of 
HCC recurrence in patients with detectable HBV DNA in 
serum (B1).
6.  After curative treatment of HCV-associated HCC, the 
association of DAA therapy with risk or prevention of 
HCC recurrence is not yet clear (C1).
7.  Coffee consumption in patients with chronic liver 
disease can lower the risk of HCC (B1).
Surveillance
The major rationale for intensive surveillance for cancer 
is to reduce disease-related mortality. There are only two 
RCTs on the efficacy of surveillance programs in reducing 
HCC-related mortality among individuals at risk of HCC. 
In a Chinese study of 5581 chronic hepatitis B patients 
recruited in the early 1990s, surveillance for HCC using 
only 6-monthly alpha-fetoprotein (AFP) assays resulted in 
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earlier diagnosis of HCC; however, the gain in lead time 
did not result in a significant reduction in overall mortality 
because of ineffective treatments for HCC (60). In contrast, 
a large-scale trial involving 18816 Chinese patients with 
chronic hepatitis B demonstrated that, despite poor 
study adherence (58.2%), a strategy of surveillance with 
ultrasonography (US) and AFP measurement every 6 
months significantly reduced HCC-related mortality by 37% 
compared with no surveillance. In addition, the surveillance 
strategy was associated with a higher rate of detection of 
small HCC and surgically amenable HCC, as well as better 
overall survival (OS) after the diagnosis of HCC (61). Several 
non-randomized cohort studies and meta-analyses have also 
found that surveillance has detected more cases of early-
stage HCC, provided a higher rate of curative treatments, 
and led to significantly better OS than that found in the 
control group, indicating the compelling justification for 
HCC surveillance in at risk patients (62-66).
Unlike other malignancies, HCC has well-established risk 
factors that allow the identification of an at risk patient 
group. Since approximately 90% of HCC cases are associated 
with a well-known risk factor, most of the international 
guidelines have been adapted to perform HCC surveillance 
in the population at risk of HCC development (63). Patients 
with cirrhosis derived from any etiology are regarded as the 
most important targets to perform a surveillance program, 
since more than 80% of patients diagnosed with HCC have 
underlying cirrhosis. Viral hepatitis is also one of the most 
important causal risk factors for HCC. Chronic HBV infection 
is responsible for around 70% of all patients diagnosed 
with HCC in East Asia, including Korea, whereas chronic 
HCV infection accounts for around 30% of HCC patients in 
Western countries, with most of the HCV-associated HCC 
patients having either cirrhosis or advanced fibrosis at 
diagnosis. However, one Korean study involving patients 
undergoing hepatectomy has shown that 32.5% of HCV-
related HCCs were not associated with underlying cirrhosis, 
indicating a lower rate of HCV-related HCC accompanying 
cirrhosis than that reported in Western countries (67). 
In addition, the risk of HCC also increases with patient 
age, excessive alcohol drinking, male sex, and diabetes 
mellitus, and is higher among Asian HBV carriers with 
high viral activity and family history of the disease, and 
chronic hepatitis B patients with cirrhosis or advanced 
fibrosis (68, 69). Based on a cost-effectiveness study, 
it is generally accepted that an annual incidence of HCC 
surpassing 1.5% would warrant a surveillance scheme of 
HCC in cirrhosis patients (70). However, patients with 
chronic HBV infection can develop HCC in the absence of 
underlying cirrhosis. Thus, expert opinion indicates that 
HCC surveillance for chronic HBV carriers is deemed to be 
cost-effective if the annual incidence is at least 0.2% (71). 
Given this definition, patients with liver cirrhosis of all 
etiologies, chronic HBV infection, or chronic HCV infection 
with cirrhosis or advanced fibrosis are the major target 
population for surveillance as a high risk group for HCC. 
From a pooled analysis of previously published studies on 
the natural history of various liver diseases, patients with 
liver cirrhosis are at the highest risk of developing HCC, 
irrespective of etiology. Patients with chronic HBV infection 
and those with HCV-related cirrhosis or advanced fibrosis 
are also at a high risk of HCC, of which annual incidences 
exceed 0.2% and 1.5%, respectively (63, 71). The major 
drawbacks that remain are the difficulties in accurately 
defining cirrhosis in alcoholic or all other liver diseases, 
as well as differentiating F3 from F2 disease in hepatitis C. 
The role of HCC surveillance is unclear among patients with 
non-viral liver disease and there is uncertainty regarding 
underlying cirrhosis. Although age is an important risk 
factor for HCC, there is no clear evidence to guide the target 
population according to age strata. With the exception of 
cirrhosis patients with alcoholic or nonalcoholic fatty liver 
disease, there are few data available on the actual HCC risk 
and surveillance and thus, a solid recommendation cannot 
be made for those with fatty liver disease.
In general, US with or without AFP is widely used 
as a tool for HCC surveillance. However, there is some 
discrepancy regarding the recommended surveillance 
methods. Among tumor markers relevant to HCC, no factors 
have actually been proven to be better in detecting HCC 
than AFP. Consequently, information on tumor markers 
for HCC surveillance is limited to AFP, since almost all 
studies looking at the effectiveness of a surveillance 
program have implemented only AFP as a tumor marker 
for HCC. The sensitivity of detecting early stage HCC in 
high-risk patients is reportedly approximately 60% when 
performing surveillance using US with and without serum 
AFP measurement (72-74). The sensitivity and specificity of 
US as a surveillance tool for HCC in patients with chronic 
HBV infection were reported to be 65–80% and over 90%, 
respectively, with a higher sensitivity for detecting liver 
cancer than that of serum markers such as AFP (66, 75). 
While AFP measurement and US are imperfect tools, they 
appear to be mutually complementary (69). From a meta-
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analysis of 16 relevant studies, combined use of US and AFP 
measurement yielded a higher sensitivity for HCC detection 
than US alone (0.79 [95% CI, 0.57 to 0.91) vs. 0.69 
[95% CI, 0.46 to 0.85]), although it was not statistically 
significant (62). In another meta-analysis of 13 selected 
studies, the pooled sensitivity for detecting early-stage 
HCC increased from 63% with US alone to 70% with US plus 
AFP measurement (62). A pooled analysis of seven studies 
of patients with cirrhosis showed that US with versus 
without AFP measurement detected early-stage HCC with 
63% sensitivity (95% CI, 48% to 75%) and 45% sensitivity 
(95% CI, 30% to 62%), respectively, indicating a higher 
sensitivity with US plus AFP measurement than US only 
(76). The performance of surveillance varies depending on 
the cutoff levels of biomarkers and the prevalence of HCC 
among the general population in a certain region. In the 
United States and Europe where the prevalence of HCC is 
relatively low, only US examination is often recommended 
as a surveillance method, whereas in Korea and Japan 
where its prevalence is high, it is recommended to perform 
US with serum AFP measurement for HCC surveillance in the 
high-risk population (77-79).
The interval of cancer surveillance should be determined 
based on tumor doubling time, stage migration amenable 
for curative treatments at diagnosis, cost-effectiveness, 
and patient survival. Although the optimal surveillance 
intervals in at risk patients for HCC have not yet been 
clearly determined, the intervals of HCC surveillance 
recommended by most of the regional guidelines range from 
3 to 12 months (71, 77-80). An Italian study comparing 
6-month versus 12-month surveillance failed to increase the 
chances of detection of single nodular tumors with 6-month 
surveillance compared with 12-month surveillance (81). An 
RCT evaluating more intense surveillance of 3-month versus 
6-month intervals also only provided similar results in 
detecting small HCCs (82). In contrast, another Italian study 
looking at the performance for the early detection of HCC 
showed that semiannual surveillance increases the detection 
rate of early-stage HCC and patient survival compared with 
an annual program (65). Another randomized trial that 
evaluated US as a surveillance tool in Taiwanese patients 
with viral hepatitis demonstrated that a 4-month interval 
scheme performed better in detecting very early stage HCC 
compared with that of a 12-month interval, although it did 
not provide a survival benefit (83). Moreover, the pooled 
sensitivity of detecting HCC increased from 50% with the 
annual scheme to 70% with the semiannual surveillance 
(62). In a cost-effective study, a semiannual US surveillance 
program in cirrhotic patients provided an incremental cost-
effectiveness ratio and improved clinical outcomes at a 
reasonable cost (84). The mean tumor doubling time of 
small HCCs (< 5 cm) was estimated to be around 4 to 7 
months, ranging between 136 and 204 days (85, 86). Lastly, 
semiannual surveillance is the interval employed in the only 
RCT that showed survival benefits with an HCC surveillance 
scheme (61). Thus, taken together, a 6-month interval 
for an HCC surveillance program would be considered a 
preferable and reasonable strategy.
Given that the incidence of HCC varies according to the 
cause of liver disease and the degree of cirrhosis even in 
the high-risk group, there may be groups at higher risk 
of HCC than others. Under circumstances in which HCC is 
highly suspected, contrast-enhanced US, liver dynamic 
computed tomography (CT), or contrast-enhanced magnetic 
resonance imaging (MRI) can be performed as an alternative 
to US when a US examination fails to detect nodules or is 
incomplete due to poor visualization. With the advantage 
of assessing blood supply and vascular invasion of tumors, 
contrast-enhanced US has been found more cost-effective 
in surveillance for HCC than US alone (87).
A recent randomized trial comparing biannual US with 
yearly contrast CT has shown the former to be marginally 
more sensitive and less costly for the detection of early HCC 
in patients with compensated cirrhosis (88). More recently, 
MRI with liver-specific contrast in a surveillance setting of 
cirrhotic patients has resulted in a higher detection rate of 
HCC and lower falsepositive findings than US (89). However, 
the information on the alternative surveillance imaging 
strategies is very limited and should be interpreted with 
caution. Study results regarding the diagnostic performance 
of CT or MRI for HCC cannot be directly extrapolated to 
the setting of cancer surveillance. In addition, the risks, 
accessibility, and cost-effectiveness of these alternative 
imaging methods should be meticulously evaluated. 
Therefore, accuracy, costs, and potential harms regarding 
these new radiological modalities need to be further 
studied before the wide implementation of the alternative 
surveillance imaging strategies.
[Recommendations]
1.  Surveillance for HCC should be performed in high-risk 
groups; patients with chronic hepatitis B (A1), chronic 
hepatitis C (B1), and liver cirrhosis (A1).
2.  Surveillance test for HCC should be performed with 
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liver US plus serum AFP measurement every 6 months 
(A1).
3.  If liver US cannot be performed properly, liver dynamic 
CT or dynamic contrast-enhanced MRI can be performed 
as an alternative (C1).
Diagnosis
HCC can be diagnosed either pathologically with a biopsy 
or with noninvasive imaging in high-risk groups with 
chronic hepatitis B, chronic hepatitis C, or cirrhosis. In at-
risk patients with a nodule ≥ 1 cm in size on surveillance 
tests, a first-line imaging test should be performed, such as 
multiphase CT or multiphase MRI with extracellular contrast 
agents or hepatobiliary contrast agents like gadolinium 
ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-
DTPA). Diagnostic imaging tests are used to diagnose HCC 
and determine its extent. As imaging-based diagnosis relies 
on the typical findings of multiphase CT or MRI; single-
phase CT or MRI cannot be used as a diagnostic tool for 
HCC.
A recent meta-analysis regarding the diagnostic 
performances showed a per-lesion sensitivity of 76% (95% 
CI, 72% to 80%) for multiphase CT and 83% (95% CI, 80% 
to 86%) for multiphase MRI, respectively (72). Per-patient 
specificities were 91% (95% CI, 84% to 95%) for multiphase 
CT and 89% (95% CI, 82% to 93%) for multiphase MRI, 
respectively (72). In addition, several meta-analyses 
reported that MRI using hepatobiliary contrast agents was 
associated with higher sensitivity (hepatobiliary contrast 
agents, 85.6%; 95% CI, 81.1% to 87.7% vs. extracellular 
contrast agents, 77.5%; 95% CI, 73.1% to 79.3%) and a 
higher positive predictive value (hepatobiliary contrast 
agents, 94.2%; 95% CI, 90.9% to 96.3% vs. extracellular 
contrast agents, 83.6%; 95% CI, 77.2% to 87.5%) than 
those using extracellular contrast agents (90, 91).
When an imaging diagnosis of HCC cannot be made 
with confidence on a first-line examination, a second-line 
examination with an alternative modality or contrast agent 
can be applied to enhance the sensitivity to diagnose HCC 
(92, 93). Imaging modalities for second-line examinations 
include multiphase CT, multiphase MRI with extracellular 
contrast agents or hepatobiliary contrast agents, and 
contrast-enhanced US with blood pool contrast agents. 
Contrary to the previous concern regarding its potential 
risk of misdiagnosing cholangiocarcinoma as HCC, contrast-
enhanced US with blood pool contrast agents had a high 
specificity for HCC in a recent large retrospective study 
(94). A meta-analysis found that contrast-enhanced US was 
comparable to multiphase CT and MRI with extracellular 
contrast agents in terms of sensitivity, which was 84.4% 
(95% CI, 79.4% to 86.7%) and positive predictive value, 
which was 89.3% (95% CI, 85.7% to 92.5%) (91). A 
prospective multicenter trial revealed that contrast-
enhanced US had very high specificity for HCC diagnosis 
as a second imaging technique after a first inconclusive 
CT or MRI (95). Because contrast-enhanced US is limited 
in evaluating the tumor extent in the whole liver (i.e., 
radiologic staging), it is not recommended as a first-
line imaging modality. Instead, contrast-enhanced US is 
recommended as a second-line imaging technique if first-
line imaging is inconclusive. In patients with early HCC, 
addition of MRI with Gd-EOB-DTPA to multiphase CT led 
to the detection of additional small nodules in 16.4% of 
patients and stage migration in 13.3%, which decreased 
the risk of HCC recurrence and lowered the mortality rate by 
28% and 35%, respectively (96).
Noninvasive diagnosis of “definite” HCC is based on 
the typical imaging hallmarks of HCC on multiphase CT 
or multiphase MRI with extracellular contrast agents or 
hepatobiliary contrast agents for a nodule ≥ 1 cm detected 
in at risk patients. The major imaging features for a 
“definite” diagnosis of HCC are defined as arterial phase 
hyperenhancement with washout in the portal venous, 
delayed, or hepatobiliary phases (Table 2, Figs. 3, 4). If the 
size of newly detected nodule(s) during surveillance tests 
is smaller than 1 cm, follow-up US in 6 months or less is 
recommended.
On multiphase MRI with a hepatobiliary phase agent, 
washout can be considered present if a nodule shows 
hypoenhancement relative to the surrounding hepatic 
parenchyma not only during the portal or delayed phases 
but also during the hepatobiliary phase. The classic 
imaging hallmarks of HCC, which were adopted in previous 
guidelines, include arterial phase hyperenhancement 
and washout confined to the portal or delayed phases. 
Based on these diagnostic criteria, prospective studies 
demonstrated that multiphase CT or MRI with extracellular 
contrast agents had a sensitivity of 65% to 89% and a 
specificity of 91% to 100% (92, 93). In spite of the high 
specificity, the sensitivity of HCC diagnosis under these 
criteria is limited, which is even worse in nodules smaller 
than 2 cm where it only shows a sensitivity of 41% to 62% 
(97, 98). When hypointensity in the hepatobiliary phase is 
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considered as washout, the sensitivity is increased (99-101). 
Given the medical environments in Korea characterized 
by the wide use of MRI with hepatobiliary contrast agents 
and an emphasis on early detection and treatment, the 
diagnostic criteria for HCC should aim for high sensitivity. 
Thus, this guideline defines washout in the portal, delayed, 
and hepatobiliary phases. However, the usefulness of this 
approach can be offset by misdiagnosis of hemangioma 
and cholangiocarcinoma as HCC (101). The diagnostic 
criteria for HCC should not be applied in lesions showing 
marked T2 hyperintensity or targetoid appearance on 
diffusion-weighted images or contrast-enhanced sequences, 
which are typical imaging features of hemangioma or 
cholangiocarcinoma. Eosinophilic infiltration in the liver, 
which is common in Korean patients, can also mimic 
HCC (102). In order to avoid this pitfall, the peripheral 
eosinophil count needs to be determined before making a 
diagnosis of HCC. The typical hallmark for “definite” HCC 
Table 2. Diagnosis of Hepatocellular Carcinoma
1.  Imaging diagnosis: In at risk patients (chronic hepatitis B, chronic hepatitis C, and liver cirrhosis) having lesion ≥ 1 cm on 
surveillance tests
(1)  Non-invasive diagnosis of “definite” HCC is based on typical imaging hallmarks of HCC on multiphase CT or multiphase MRI with 
extracellular contrast agents or hepatobiliary contrast agents.
If first-line imaging is inconclusive, second line examination can be applied. Imaging modalities for second line examinations 
include multiphase CT, multiphase MRI with extracellular contrast agents or hepatobiliary contrast agents, and contrast-enhanced 
US with blood pool contrast agents.
(2)  Major imaging features for “definite” diagnosis of HCC are defined as arterial phase hyperenhancement with washout in portal 
venous, delayed or hepatobiliary phases. These criteria should be applied only to lesion which does not show either marked T2 
hyperintensity or targetoid appearance on diffusion-weighted images or contrast-enhanced sequence.
(3)  Typical hallmark for “definite” HCC diagnosis at contrast-enhanced US is defined as arterial phase hyperenhancement followed by 
late (> 60 seconds) washout of mild degree.
(4)  In nodule(s) with some but not all aforementioned major imaging features of HCC, category of “probable” HCC can be assigned 
by applying ancillary imaging features.* This category should be applied only to lesion(s) which does not show either marked T2 
hyperintensity or targetoid appearance on diffusion-weighted images or contrast-enhanced sequence.
2. Pathologic diagnosis
When imaging-based diagnosis inconclusive or lesion(s) shows atypical imaging features, biopsy is indicated.
*Ancillary imaging features are summarized in Table 3. CT = computed tomography, HCC = hepatocellular carcinoma, MRI = magnetic 
resonance imaging, US = ultrasound
Fig. 3. Typical hallmarks of HCC (arrows) on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid MRI. 
A. T2-weighted image. B. Diffusion-weighted image. C. Non-contrast image. D. Arterial phase image. E. Portal phase image. F. Delayed phase 
image. G. Hepatobiliary phase image. HCC = hepatocellular carcinoma, MRI = magnetic resonance imaging
A
E
B
F
C
G
D
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diagnosis on contrast-enhanced US is defined as arterial 
phase hyperenhancement followed by late (> 60 seconds) 
washout of a mild degree (90). In a nodule with some but 
not all of the aforementioned major imaging features of 
HCC, a diagnosis of “probable” HCC can be made by applying 
ancillary imaging features (Table 3, Fig. 4). This category 
Newly detected lesion during surveillance
in high risk patients (CHB, CHC, and LC)
First-line exams
Multiphase CT, multiphase MRI with ECF
contrast agents or EOB
Follow-up US within 6 months
Definite HCC
Probable HCC†
Follow-up studies
within 6 months or consider biopsy
Follow-up studies or
consider biopsy
Indeterminate nodule
Second-line exams
Multiphase CT, multiphase MRI with ECF contrast
agents or EOB, and contrast-enhanced US with
blood-pool contrast agent
No
No
No
Yes
Yes
Yes
Yes
≥ 1 cm
Major imaging
features of HCC*
Major imaging
features of HCC*
Ancillary imaging
features of HCC†
Fig. 4. Diagnostic algorithm and recall policy in patients with high risk of HCC. *Major imaging features for “definite” diagnosis of 
HCC are defined as arterial phase hyperenhancement with washout in portal venous, delayed or hepatobiliary phases. These criteria should be 
applied only to lesion which does not show either marked T2 hyperintensity or targetoid appearance on diffusion-weighted images or contrast-
enhanced sequence on contrast-enhanced US as second line exams, major imaging features include arterial hyperenhancement and mild washout 
with late onset (≥ 60 seconds), †In nodule(s) with some but not all of aforementioned major imaging features of HCC, category of “probable” HCC 
can be assigned only when lesion fulfills at least one item from each of following two categories of ancillary imaging features. Two categories 
which make up ancillary imaging features are findings favoring malignancy in general (mild-to-moderate T2 hyperintensity, restricted diffusion, 
hepatobiliary phase hypointensity, interval growth) and those favoring HCC in particular (non-enhancing capsule, mosaic architecture, nodule-in-
nodule appearance, fat or blood products in mass). These criteria should be applied only to lesion which shows neither marked T2 hyperintensity 
nor targetoid appearance on diffusion-weighted images or contrast-enhanced sequences. CHB = chronic hepatitis B, CHC = chronic hepatitis C, 
CT = computed tomography, ECF = extracellular fluid, EOB = gadolinium ethoxybenzyl diethylenetriamine pentaacetate, LC = liver cirrhosis, US = 
ultrasonography
No
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should be applied only to a lesion which does not show 
either marked T2 hyperintensity or a targetoid appearance 
on diffusion-weighted images or contrast-enhanced 
sequence. “Probable” HCC in this guideline corresponds 
to LR-4 (probable HCC) according to the Liver Imaging 
Reporting and Data System proposed by the American 
College of Radiology (90). For “probable” HCC, a follow-
up imaging study with an interval of less than 6 months or 
biopsy needs to be considered to establish the diagnosis.
Recent advances in imaging techniques have provided 
more opportunities to detect subcentimeter-sized lesions. 
Some HCC guidelines from Asian countries allow the 
diagnosis of subcentimeter-sized HCCs (79, 103, 104). 
However, the diagnostic performances of imaging studies 
for subcentimeter-sized HCCs are worse than those for 
HCCs ≥ 1 cm (< 1 cm vs. ≥ 1 cm: 31% vs. 82%, p < 0.001 
for CT; 48% vs. 88%, p = 0.02 for MRI) (90). Even MRI 
with hepatobiliary contrast agents showed significantly 
lower per-lesion sensitivity (46%) and positive predictive 
value (48%) for subcentimeter-sized HCCs than those for 
HCCs ≥ 1 cm (sensitivity, 95%; positive predictive value, 
78%) (105). Recent studies found that adding the ancillary 
imaging features (Table 3, Fig. 4) improved diagnostic 
performances for subcentimeter-sized HCCs (105-109). A 
subcentimeter-sized lesion should not immediately initiate 
the recall process. Instead, a conservative approach should 
be preferred, with close monitoring of interval growths or 
changes in follow-up imaging studies at an interval of less 
than 6 months.
When the imaging diagnosis using the first- and second-
line examinations remains inconclusive for a nodule 
detected during surveillance tests in at risk patients, the 
lesion is defined as “indeterminate.” A study including more 
than 90 cases of 1 to 2 cm-sized indeterminate nodules 
found on surveillance revealed that the prevalence of 
malignancy was 14% to 23%, while the remaining lesions 
were diagnosed as arterioportal shunt, regenerative nodules, 
and dysplastic nodules (110). Thus, for indeterminate 
lesions in at risk patients, any changes in imaging patterns 
or serum tumor markers should be closely monitored, or 
biopsy can be considered for pathologic diagnosis.
For pathologic diagnosis of HCC, biopsy is considered a 
relatively safe procedure. However, in clinical practice, it is 
often difficult to perform due to the presence of ascites, a 
high risk of bleeding associated with poor hepatic function, 
concerns for needle track seeding, and challenges in tumor 
targeting. Among the techniques used to obtain a tissue, 
core needle biopsy should be preferred instead of fine 
needle aspiration cytology or fine needle aspiration biopsy. 
Sensitivity of pathologic diagnosis for HCC is reported as 
approximately 72%, although it varies according to the 
location, size and degree of differentiation (111, 112). The 
pathological diagnosis is more challenging for small HCCs 
less than 2 cm (111, 112). Sensitivity can be even worse, 
considering that the adequate biopsy sampling of such 
small lesions is challenging (111). Cytologic examination 
methods, such as fine needle aspiration cytology and fine 
needle aspiration biopsy, may be helpful for the diagnosis of 
advanced HCC (≥ grade 2). As the risk of tumor seeding was 
0.6% to 5.1%, its rationale in patients who have a chance 
for complete treatment after surgery or liver transplantation 
has been questioned (113, 114). The presence of stromal 
invasion, which is a criterion to differentiate between 
early HCC and dysplastic nodule, cannot be determined 
competently using liver biopsy (111, 112). In addition, 
liver tumor biopsy is associated with a 33% risk of false 
positive results (111, 112). Thus, the majority of diagnoses 
in clinical practice are made on the basis of noninvasive 
imaging studies. However, imaging sometimes fails to 
differentiate infrequent subtypes of primary hepatic 
tumors, including combined HCC and cholangiocarcinoma 
(combined HCC-CC) and cholangiocellular carcinoma, 
from HCC. Therefore, biopsy is required when a definite 
diagnosis cannot be made using the imaging criteria 
or atypical hepatic tumors do not follow an expected 
clinical course. Histologic markers, including heat shock 
protein 70, glypican 3, and glutamine synthetase, can be 
assessed to distinguish HCC from dysplastic nodules (115). 
Table 3. Ancillary Imaging Features
Favoring malignancy in general
Mild-to-moderate T2 hyperintensity, restricted diffusion, hepatobiliary phase hypointensity, 
  threshold growth*
Favoring HCC in particular
Non-enhancing capsule, mosaic architecture, nodule-in-nodule appearance, fat or blood products 
  in mass
Ancillary features favoring benignity Size stable ≥ 2 years*, marked T2 hyperintensity, no mass effect
*Threshold growth is now defined as increase in size of nodule by at least 5 mm and at sufficient rate: either ≥ 50% increase in size in ≤ 6 
months or ≥ 100% increase in size in > 6 months (90).
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Unresponsiveness to treatment can also be an indication for 
liver biopsy.
The role of tumor markers is limited in the diagnosis of 
HCC due to their high false positive and false negative rates 
(116). AFP levels stay within the normal range in 35% of 
patients with small HCCs, whereas AFP levels can be elevated 
not only in HCC but also in nonspecific conditions, such as 
aggravation of hepatitis activity or active regeneration of 
hepatocytes (74, 117, 118). Therefore, AFP measurement 
alone is not sufficient to make a diagnosis of HCC.
Little is known about the imaging diagnosis criteria for 
recurrent hepatic tumors. However, given the high pre-
test probability of recurrence in patients with a history 
of previous HCC, high sensitivity can be pursued in this 
setting. A diagnosis of HCC for newly detected or growing 
nodules in follow-up imaging studies can be more easily 
achieved using ancillary features in patients who have a 
history of HCC, even when the lesions are smaller than 1 cm 
or do not show the typical characteristics.
Risk of Radiation Exposure Dose of CT 
Examination in HCC Patients
A study of low-dose radiation in atomic bomb survivors 
indicates a significant increase in cancer risk even from 
acute exposure to 10–50 mSv radiation (119). In addition, 
studies of occupational radiation exposure suggest that 
protracted exposure to 50–100 mSv can increase cancer 
risk in humans (120-122). The International Commission 
on Radiological Protection (ICRP) reports that the cancer 
risk after radiation exposure exhibits a linear-nonthreshold 
dose-response relationship (123, 124). However, there is no 
report on direct diagnostic X-ray radiation exposure-related 
cancer risk. The dose of radiation exposure of 4-phase liver 
dynamic CT is approximately 20–30 mSv. According to the 
BEIR VII phase 2 trial by the Committee to Assess Health 
Risks from Exposure to Low Levels of Ionizing Radiation, the 
additional lifetime attributable solid cancer and leukemia 
incidence and mortality rates are 0.148% and 0.09%, 
respectively, in 50-year-old men with 25 mSv X-ray radiation 
exposure after a 4-phase liver dynamic CT (125, 126). The 
ICRP 2007 recommendations are as follows: “The limitation 
of the dose to the individual patient is not recommended 
because it may, by reducing the effectiveness of the 
patient’s diagnosis or treatment, do more harm than good. 
The emphasis is then on the justification of the medical 
procedures and on the optimization of protection” (127). In 
addition, the radiation-associated cancer risk is considered 
less significant in patients with decreased life expectancy, 
such as elderly or severely ill patients (128). Thus, strict 
limitation of the radiation dose of CT is not recommended 
for the diagnosis and follow-up evaluation of HCC. However, 
unnecessary radiation exposure from CT should be avoided 
and alternative imaging studies should be considered, 
particularly in patients with long life expectancy. Recently, 
CT techniques with a reduced radiation dose using iterative 
reconstruction and low voltage have been developed, 
without compromising image quality (129, 130). Thus, 
these low-dose techniques or alternative imaging methods, 
such as MRI, need to be considered in order to optimize 
radiation exposure.
[Recommendations]
1.  A diagnosis of HCC can be made with either pathology 
or noninvasive imaging in high-risk groups (chronic 
hepatitis B, chronic hepatitis C, or cirrhosis) (A1).
2.  In at risk patients with a lesion ≥ 1 cm in size on 
surveillance tests, multiphase CT or multiphase MRI 
with extracellular contrast agents or hepatobiliary 
contrast agents should be performed as a first-line 
examination (A1). If first-line imaging is inconclusive, 
second-line imaging examination can be applied. The 
second-line imaging examinations include multiphase 
CT, multiphase MRI with extracellular contrast agents 
or hepatobiliary contrast agents, and contrast-
enhanced US with blood pool contrast agents (B1).
3.  An imaging diagnosis can be applied to a nodule ≥ 1 
cm detected in at risk patients during surveillance on 
the basis of the following radiologic hallmarks:
(1)  On multiphase CT or MRI with extracellular contrast 
agents, the major imaging features for a “definite” 
diagnosis of HCC are defined as arterial phase 
hyperenhancement with washout in the portal 
venous or delayed phases (A1).
(2)  On multiphase MRI with hepatobiliary contrast 
agents, the major imaging features for a “definite” 
diagnosis of HCC are defined as arterial phase 
hyperenhancement with washout in the portal 
venous, delayed, or hepatobiliary phases. These 
criteria should be applied only to a lesion which 
does not show either marked T2 hyperintensity or a 
targetoid appearance on diffusion-weighted images 
or contrast-enhanced sequences (B1).
4.  In nodule(s) with some but not all of the 
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aforementioned major imaging features of HCC, the 
category of “probable” HCC can be assigned only when 
the lesion fulfills at least one item from each of the 
following two categories of ancillary imaging features 
(B1). The two categories which make up ancillary 
imaging features are findings favoring malignancy in 
general (mild-to-moderate T2 hyperintensity, restricted 
diffusion, hepatobiliary phase hypointensity, interval 
growth) and those favoring HCC in particular (non- 
enhancing capsule, mosaic architecture, nodule-in-
nodule appearance, fat or blood products in the mass). 
These criteria should be applied only to a lesion which 
shows neither marked T2 hyperintensity nor a targetoid 
appearance on diffusion-weighted images or contrast-
enhanced sequences.
5.  For “probable” HCC, follow-up imaging studies in 
less than 6 months or biopsy need to be considered 
to establish the diagnosis (C1). For indeterminate 
lesions, any changes in imaging patterns or serum 
tumor markers should be closely monitored, or biopsy 
can be considered for pathologic diagnosis (B1).
6.  In patients with subcentimeter-sized nodules, 
follow-up with an interval of less than 6 months 
is recommended while closely monitoring interval 
growths or changes in imaging patterns (C1).
7.  A new or a growing nodule which does not show 
typical imaging hallmarks of HCC found in the follow-
up of a patient diagnosed with HCC could be diagnosed 
as HCC based on ancillary imaging features (C1).
8.  Although strict limitation of the radiation dose from 
CT for diagnosis and follow-up evaluation of HCC is 
not recommended, unnecessary radiation exposure 
from CT should be avoided. Techniques with a reduced 
radiation dose and alternative imaging studies should 
be considered (C1).
Staging
Cancer staging plays a pivotal role in predicting prognosis 
as well as in selecting the therapy to maximize survival 
potential. It also facilitates exchange of information and trial 
design. Prediction of the prognosis in HCC patients is complex 
because underlying liver function also affects prognosis (131, 
132). Although several staging systems for patients with HCC 
have been devised, there is no global consensus (133).
The American Joint Committee on Cancer (AJCC) has led a 
collaborative effort with the Union for International Cancer 
Control (UICC) to maintain a cancer staging system since 
1959. This system classifies the extent of disease mostly 
on the basis of anatomic information on the extent of the 
primary tumor, regional lymph nodes, and distant metastases 
(i.e., the tumor-node-metastasis [TNM] staging system) 
and has been modified repeatedly. The eighth edition 
was proposed in 2017. The guidelines from the KLCA (ex-
KLCSG) and the NCC Korea adopted the fifth version of the 
modified UICC (mUICC) staging system as a primary staging 
system for HCC in 2003 (134, 135). Thus, the continuing 
use of this staging system may facilitate consistency in 
the analyses of registry data (Table 4) (79). However, the 
mUICC staging system lacks international validation and has 
limitations, such as the difficulty of extensive international 
information exchange because it differs from the AJCC/UICC 
TNM staging system. In addition, the revised mUICC staging 
system (135) has been applied to the same stage of biliary 
tract invasion and vascular involvement. The reason for 
this is unclear, and biliary tract invasion differs in terms of 
the indication of surgery and the prognosis after treatment 
compared with vascular invasion; therefore, research to 
verify this guideline is necessary. In addition to dynamic 
CT or MRI of the primary liver tumor, chest CT, bone, and 
positron emission tomography (PET)-CT scans may be 
required to stage HCC. The risk of distant metastasis is low 
for patients with early-stage HCC; therefore, tests for the 
evaluation of extrahepatic metastasis should be carefully 
selected. Gastroscopic examination is necessary to confirm 
the presence of portal hypertension, which is important in 
making the treatment decision.
The Barcelona Clinic Liver Cancer (BCLC) staging system 
includes factors for tumor stage, degree of liver function, 
and performance status of the patient. It suggests the most 
recommendable treatment modality for each stage and 
is endorsed by the American Association for the Study of 
Liver Diseases (AASLD), the European Association for the 
Study of the Liver (EASL), and the European Organization 
for Research and Treatment of Cancer (77, 136). However, 
the use of the BCLC staging system is limited because it 
contains a subjective component (i.e., performance status), 
crude evaluation of liver function (i.e., Child-Pugh class), 
and unduly simplified recommendations for the treatment 
modality. The Hong Kong Liver Cancer (HKLC) staging 
system was developed for Asian patients, most of whom 
were hepatitis B patients. Patients with intermediate or 
advanced stage disease according to the BCLC staging 
system were more likely to have more active treatment than 
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the BCLC staging system and the survival rate was increased 
when they followed HKLC staging system. However, 
validation is required for non-Asian populations and other 
causes of liver cancer (137).
Evaluation of tumor extension is critical for determining 
the cancer stage and treatment strategy. Common sites of 
HCC metastasis include the lung, lymph nodes, bone, adrenal 
gland, and peritoneum (138). Although the indications 
and methods to detect these metastatic lesions have not 
yet been established, the recent National Comprehensive 
Cancer Network guidelines recommend chest CT, complete 
imaging of the pelvis with contrast-enhanced CT, and 
bone scan as staging workups in patients with HCC (139). 
Several meta-analyses and retrospective studies found that 
fluorodeoxyglucose F18 (18F-FDG)-PET CT appeared to be 
useful in detecting extrahepatic metastasis in patients with 
HCC (140-142). In a prospective Korean study including 
35 metastatic HCC patients, the sensitivity of 18F-FDG-PET 
CT for extrahepatic HCC lesions was reported to be up to 
85.7% (140). In particular, the detection rates of lung and 
bone metastases, which were the most common types of 
HCC metastases, were 80% and 100%, respectively. Another 
Korean study also demonstrated that 5% of BCLC stage A (6 
of 119) and 1.4% of BCLC stage B (1 of 71) HCC patients 
were shifted to BCLC stage C after identifying extrahepatic 
lesions using 18F-FDG-PET CT (143). Hence, 18F-FDG-PET CT 
can be selectively considered for patients with HCC prior to 
curative surgical treatments, such as hepatectomy and liver 
transplantation.
[Recommendations]
1.  This guideline adopts the mUICC stages as a primary 
staging system, with the BCLC staging system 
and the AJCC/UICC TNM staging system serving as 
complementary systems (B1).
2.  The use of 18F-FDG-PET CT is suggested to detect the 
presence of metastatic disease in the case of patients 
being considered for treatments with curative intent, 
such as hepatic resection and liver transplantation (C1).
3.  Chest CT, pelvis CT, and bone scan can be used as part 
Table 4. Modified Union for International Cancer Control Stage*
Stage T N M
I T1 N0 M0
II T2 N0 M0
III T3 N0 M0
IV A T4 N0 M0
T1, T2, T3, T4 N1 M0
IV B T1, T2, T3, T4 N0, N1 M1
Criteria T1 T2 T3 T4
(1)  Number of tumors:  
solitary
(2)  Diameter of largest  
tumor ≤ 2 cm
(3)  No vascular or bile duct 
invasion: Vp0, Vv0, B0
All three criteria are
  fulfilled
Two of three
  criteria are fulfilled
One of three criteria
  is fulfilled
None of three criteria
  are fulfilled
*Adapted from Liver Cancer Study Group of Japan (134, 135). B = bile duct invasion, M = metastasis, N = node, T = tumor, Vp = portal 
vein invasion, Vv = hepatic vein invasion
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of the HCC staging workup if extrahepatic metastasis 
of HCC is suspected (C1).
Management Overview
The ultimate goal of treatment for HCC patients may vary 
depending on the patient’s cancer stage, underlying liver 
function and performance status; however, generally the 
goal is to increase the survival time and rate and improve 
quality of life. This requires multidisciplinary treatment 
planning, including gastroenterology, hepatology, oncology, 
surgery, radiology, interventional radiology, radiation 
oncology, pathology, and many other departments.
Therapies should be selected on the basis of strong 
evidence, and the best evidence is from meta-analyses, 
RCTs, prospective controlled studies, and prospective large-
scale cohort studies that verify the survival rate. Even 
though these studies are increasing, the best evidence like 
RCTs regarding HCC treatment is still insufficient, and thus 
a great part of treatment planning is based on moderate 
level evidence. Therefore, applying treatments requires 
great understanding of the whole of HCC. It is difficult to 
establish a balanced and multidisciplinary treatment plan in 
actual clinical practice because treatment indications and 
results claimed by each department that directly performs 
treatment lack objectivity. Accordingly, more objective 
evaluation is necessary through group discussions of expert 
groups, such as the KPGRC.
The best treatments recommended in these guidelines are 
the results of evidence-based medicine. Prerequisites for 
the application of these recommendations include actual 
facilities and trained personnel to provide all possible 
treatments for the patients, as well as the financial 
conditions of patients and cooperation of patients and 
guardians. Therefore, these guidelines first provided both 
the best and alternative treatments for HCC according 
to mUICC staging in 2014 considering the various 
aforementioned requirements, and the same approach 
is taken in the revised guidelines (Fig. 5). However, as 
different treatments may be selected for HCC depending 
on underlying liver function and competency in addition 
to staging, not all possible cases could be listed and 
summarized in these guidelines. Recommendations for 
specific treatments are made on the basis of medical 
evidence and expert opinions for various HCC conditions, 
and are described in detail in each treatment section of 
these guidelines.
This overview summarizes the treatments for HCC 
patients with various mUICC disease stages with good liver 
function (Child-Pugh A level) and good performance status 
(Eastern Cooperative Oncology Group [ECOG] performance 
0–1) without any complications of portal hypertension to 
promote understanding of treatments in general. These 
guidelines separately deal with second-line treatment for 
the first time, and this Management Overview provides 
information only on the initial treatment. Second-line 
treatments for residual, recurred, or progressed cancer after 
the initial treatment are described separately along with 
recommendations later.
Hepatic Resection
Hepatic resection is not only a primary treatment 
modality for patients with solitary HCC unaccompanied by 
liver cirrhosis (144), but also a preferentially considered 
option for cirrhosis patients with sufficient hepatic 
functional reserve (145, 146). The results of hepatic 
resection for HCC have markedly improved thanks to recent 
advances in preoperative tests and surgical skills, as well as 
accumulation of experience in postoperative management 
(147). Recent studies show that postoperative mortality 
after HCC resection is less than 1% to 3%. In addition, 
the 5-year overall and disease-free survival rates are 46% 
to 69.5% and 23% to 56.3%, respectively (148-151). The 
5-year recurrence rate after hepatic resection of HCC ranges 
from 43.7% to 77%, and 80% to 95% of postoperative 
recurrences are intrahepatic (152). Intrahepatic recurrences 
are divided into intrahepatic metastasis and de novo HCC 
by multicentric carcinogenesis. The two recurrence entities 
can be differentiated by means of genomic hybridization, 
DNA fingerprinting, DNA microarray, or HBV integration 
pattern (153). However, no clinical definition of either 
entity has been established. In general, late recurrence 
more than 2 years after primary resection is considered de 
novo HCC (154). Risk factors associated with recurrence 
after resection are classified as either tumor-related or 
underlying disease-related. Tumor-related factors, which are 
usually related to early recurrence, include tumor size and 
number, microvascular invasion, poor tumor differentiation, 
high serum AFP and prothrombin induced by vitamin K 
absence II (PIVKA-II) levels, and positivity of 18F-FDG 
PET. Meanwhile, underlying disease-related risk factors, 
which influence late recurrence, include cirrhosis, high 
serum HBV DNA levels, and active hepatitis (140, 154-
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Fig. 5. First-line treatment recommendations from 2018 Korean Liver Cancer Association-National Cancer Center, Korea Practice 
Guidelines for Patients with HCC, Child-Pugh class A, no portal hypertension, and Eastern Cooperative Oncology Group 0–1. 
EBRT = external beam radiation therapy, LRT = locoregional therapy, LT = liver transplantation, mUICC = modified Union for International Cancer 
Control, other LRT = percutaneous ethanol injection, microwave ablation, and cryoablation, RFA = radiofrequency ablation, TACE = transarterial 
chemoembolization, TARE = transarterial embolization, VI = vascular or bile duct invasion, Vp = portal vein invasion
I
Resection
RFA
mUICC stage
Single/≤ 2 cm/VI-
Single/> 2 cm/VI-
Multiple/≤ 2 cm/VI-
Multiple/≤ 2 cm/VI+
> Multiple/< 2 cm/VI+
Node +/no metastasis
Metastasis +
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Single/≤ 2 cm/VI+
> Single/< 2 cm/VI+
Best option Alternative option
TACE
Other LRT
EBRT
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Other LRT (tumor size ≤ 3 cm)
EBRT
Resection (tumor number ≤ 2)
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EBRT (tumor number ≤ 3)
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Resection
Resection
EBRT
TACE
TACE
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160). Nevertheless, no association between risk factors 
and recurrence time is evident in many cases because this 
time-dependent classification does not actually reflect the 
tumor-pathologic mechanism of HCC recurrence.
Imaging modalities, such as CT and MRI, as well as serum 
tumor markers are recommended surveillance tools during 
follow-up. Serum AFP, a traditional tumor marker of HCC, is 
also an effective marker for recurrence when liver function 
is normalized after resection in cases with preoperatively 
elevated AFP levels (161). PIVKA-II is another HCC marker 
with increasing utility for diagnosis, follow-up, and 
prognostication of HCC (155, 162).
Preoperative Evaluation
Child-Pugh classification is conventionally used to 
preoperatively assess the safety of hepatic resection (Table 
5) (163). Hepatic resection is commonly performed in 
patients with Child-Pugh class A with ECOG performance 
status 0–2 (Table 6) (164). However, Child-Pugh 
classification is an insufficient preoperative indicator 
of operability because many patients’ liver function can 
remain in Child-Pugh class A despite advanced cirrhosis 
(165, 166). Therefore, the indocyanine green 15-minute 
retention rate (ICG-R15), which was suggested for use 
in Japan, is evaluated at many Korean institutions as a 
preoperative test for the prediction of residual liver function 
(167). Although major hepatic resection is recommended 
only for patients with ICG-R15 ≤ 10%, a study recently 
reported safe right hemihepatectomy even in patients 
with an ICG-R15 of up to 14% (168). In contrast, portal 
hypertension and serum bilirubin level have been suggested 
to be criteria for resectability in Europe and the United 
States, in which portal hypertension is defined as a hepatic 
venous pressure gradient ≥ 10 mm Hg (169). Esophageal 
varix and thrombocytopenia < 100000/mm3 accompanied 
by splenomegaly are also indicators of portal hypertension, 
and thrombocytopenia is considered the most clinically 
relevant criterion (77). The posthepatectomy complication 
rate is high and the long-term prognosis is poor in patients 
with portal hypertension (169-171). However, some recent 
studies reported comparable outcomes even in patients 
with portal hypertension (172-175). Minor hepatic resection 
instead of major hepatectomy should be considered in 
patients with mild portal hypertension because resection 
volume is closely associated with the risk of postoperative 
hepatic insufficiency.
HCC is accompanied by chronic liver disease in most 
cases. Assessment of future liver volume or remnant liver 
volume after resection is as important as the hepatic 
reservoir function test  in order to predict postoperative 
hepatic insufficiency. Although 70% to 80% of the volume 
can be resected in normal liver, a much lower resection 
volume is allowed for diseased liver. There are few studies 
about the safe remnant liver volume in patients with 
Table 5. Child-Pugh Classification
1 2 3
Albumin, g/dL > 3.5 2.8–3.5 < 2.8
Bilirubin, mg/dL < 2.0 2.0–3.0 > 3.0
Prothrombin time prolonged, sec 0–4 4–6 > 6
Ascites None Slight Moderate
Encephalopathy, grade None 1–2 3–4
Class A ≤ 6 points, Class B = 7–9 points, Class C ≥ 10 points.
Table 6. Eastern Cooperative Oncology Group Performance Status*
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g.,
  light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
*Adapted from Oken, et al. Am J Clin Oncol 1982;5:649-655, with permission of Wolters Kluwer Health, Inc. (164). ECOG = Eastern 
Cooperative Oncology Group
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cirrhosis. Nevertheless, a remnant liver volume ≥ 40% is 
generally recommended in cirrhosis patients for safety (176). 
Recently, several noninvasive tests to measure the severity 
of hepatic fibrosis have been developed. Among them, 
transient elastography was recently reported to be effective 
for predicting postoperative hepatic failure and recurrence 
(177-180). Dynamic contrast-enhanced CT is the basic test 
utilized as a preoperative radiologic study to assess the 
possibility of resection. MRI using a hepatic cell-specific 
contrast medium is superior to CT for HCC detection, 
especially for small HCCs < 1 cm (181, 182), and may be 
a useful method to assess resectability and to formulate 
resection plans. Further examinations may be necessary 
to find extrahepatic metastases before liver resection in 
patients with HCC. 18F-FDG PET-CT may be effective for 
investigating extrahepatic metastasis (77, 183), although 
its sensitivity is very low for the diagnosis of intrahepatic 
HCC (140). In addition, chest CT and bone scan may be 
helpful (184).
Basic Principles of Hepatic Resection
One reason why hepatic resection has recently become 
safer is the reduction in the amount of intraoperative 
hemorrhage, thus minimizing the amount of transfused 
blood required. Blood transfusion compromises anticancer 
immunologic mechanisms and increases postoperative 
recurrence. A recent meta-analysis reports that 
intraoperative transfusion increases complication rates 
and reduces overall and disease-free survival rates after 
resection in HCC patients (185). Recent transfusion rates 
in hepatic resection are ≤ 10% owing to selective hepatic 
blood flow occlusion, maintenance of low central venous 
pressure, and precise transection of the hepatic parenchyma 
(186). Several retrospective studies (187-192) and a meta-
analysis (193) suggest that anatomical resection may be 
superior to nonanatomical resection in terms of securing 
the resection margin and removing micro-metastases. 
However, a recent prospective randomized trial showed 
that anatomical resection decreased the early recurrence 
rate within 2 years after hepatic resection, but did not 
affect 5-year disease-free survival or OS (194). Securing 
a tumor-free resection margin is absolutely critical for 
improving long-term prognosis. One prospective randomized 
trial showed that a resection margin > 2 cm led to better 
outcomes after HCC resection (195). However, although a 
sufficient margin from the tumor and anatomical resection 
are recommended, patient safety is more important because 
excessive hepatic resection can be fatal in patients with 
cirrhosis (196-198). Transarterial chemoembolization 
(TACE), performed before hepatic resection for the purpose 
of improving postoperative prognosis, is not recommended 
(199, 200) Patients with liver cirrhosis need more sufficient 
remnant liver volume than patients with normal liver 
because the remnant liver volume after hepatic resection 
is an important prognostic factor for hepatic insufficiency 
(201, 202). When insufficient remnant liver volume is 
expected, portal vein embolization before hepatic resection 
or portal vein ligation during hepatic resection may enable 
extensive hepatic resection by inducing compensatory 
hypertrophy of the residual liver (203-205). The hanging 
maneuver is frequently used during hepatic resection, 
although there is no report about the effect of the hanging 
maneuver on survival or recurrence after HCC resection. 
Nevertheless, the hanging maneuver can shorten surgical 
time and reduce the amount of bleeding (206). The anterior 
approach, which is often used for the resection of large 
tumors, is associated with less bleeding, a lower transfusion 
rate, and better survival according to one prospective study 
(207). However, its pathologic advantages require further 
evaluation.
Minimally Invasive Hepatic Resection
Laparoscopic hepatic resection has advanced rapidly, and 
its indications have been expanded. Many studies reported 
superior results of laparoscopic hepatic resection in terms 
of pain, complication rate, and hospital stay (208, 209), 
along with similar recurrence and survival rates (210, 211) 
compared with open hepatic resection for HCCs located 
in the left lateral section or on the anteroinferior surface 
of the right liver. Although laparoscopic major hepatic 
resection is increasingly being performed as well, it is 
currently limited to experienced surgeons. Accordingly, 
its efficacy and safety should be evaluated further (212). 
Robotic hepatic resection has recently been tried in very 
selected cases, and comparative studies between robotic 
hepatic resection and open or laparoscopic hepatic 
resection are needed (213, 214).
Indications for Hepatic Resection
The best prognosis after hepatic resection is generally 
expected in patients with 1 or 2 small tumors. Larger tumors 
frequently accompany vascular invasion, and result in a 
poor prognosis even after resection. However, a recent 
study showed that approximately one-third of large HCCs 
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≥ 10 cm had no vascular invasion and achieved favorable 
results after resection in those cases (215, 216). Therefore, 
the resectability for HCC should not solely be decided based 
on tumor size. Recent advances in surgical techniques and 
improvements in patient management have enabled hepatic 
resection in elderly patients with comparable short- and long-
term outcomes. Nevertheless, major hepatic resection should 
be considered with caution because the hepatic regenerative 
capability gradually decreases with age (217-219).
Although some studies reported that one-stage hepatic 
resection was an effective method for ruptured HCC in 
patients with good liver function (220, 221), hemostasis 
using TACE and subsequent elective surgery after accurate 
assessment of the hepatic functional reserve would be safer 
and more effective in hemodynamically unstable patients 
(222). However, patients with ruptured HCC have poorer 
long-term results than those with unruptured HCC (223, 
224). Hepatic resection is generally contraindicated in 
patients with evident tumor invasion to major hepatic or 
portal veins. However, except for patients with major portal 
vein invasion, the 5-year survival rate after resection of 
HCC is reported to be ≥ 30% in patients with less hepatic 
fibrosis or those with a well-differentiated HCC of low 
Edmondson-Steiner grade, with a postoperative mortality 
rate of 3.7% and median OS of 19.9 months (225-227). 
According to a Korean multicenter study, the 5-year survival 
rate of 32% after resection of HCC with bile duct invasion 
was satisfactory (227, 228) Hence, surgical resection can 
be selectively considered even for HCC with major vascular 
invasion or bile duct invasion.
[Recommendations]
1.  Hepatic resection is the first-line treatment for 
patients with intrahepatic single-nodular HCC and well-
preserved liver function of Child-Pugh class A without 
portal hypertension or hyperbilirubinemia (A1).
2.  Limited resection can be selectively applied to HCC 
patients with liver function of Child-Pugh class A 
or B7 and with mild portal hypertension or mild 
hyperbilirubinemia (C1).
3.  Hepatic resection can be considered in patients with 
three or fewer intrahepatic tumors with invasion to 
the hepatic vein, portal vein or bile duct invasion if 
hepatic function is well preserved and the main portal 
trunk is not invaded (C2).
4.  Laparoscopy-assisted resection can be considered for 
HCC located in the lateral section of the left lobe or 
the antero- inferior segment of the right lobe (B2).
Liver Transplantation
Liver transplantation is the first treatment choice for 
patients with a single tumor ≤ 5 cm or those with small 
multinodular tumors (≤ 3 nodules ≤ 3 cm) and advanced 
liver dysfunction. Liver transplantation involves complete 
removal of a diseased liver, including HCC, and replacement 
with a new liver. Theoretically, it is the ideal treatment 
method. Application of broad selection criteria in the 
early history of liver transplantation resulted in very poor 
outcomes with a 5-year survival rate of less than 40%, 
making liver transplantation a relative contraindication  at 
that time (229, 230). However, it allowed the identification 
of the best candidates and subsequent studies with a highly 
selected group of patients reported a 5-year disease-free 
survival rate of 74% (231, 232). The Milan Group in Italy 
reported an excellent result, i.e., a 4-year survival rate 
of 75% and a disease-free survival rate of 83% after liver 
transplantation in HCC patients with following conditions: 
1) no extrahepatic metastasis and no vascular infiltration 
in the radiologic study before transplantation; 2) a 
single nodule of 5 cm or less; 3) three or fewer nodules 
in cases with multiple nodules and each nodule being 3 
cm or less. Accordingly, they suggested the criteria of 
liver transplantation for patients with HCC (233). Since 
then, the Milan criteria have widely been used for liver 
transplantation in patients with HCC in various countries. A 
recent systematic review of 90 studies, comprising a total of 
17780 patients over 15 years, identified the Milan criteria 
as independent prognostic factors for outcome after liver 
transplantation. Overall 5-year survival of patients meeting 
the Milan criteria (65% to 78%) was similar compared 
with that of non-HCC patients according to European and 
American transplant registries (234-236).
Recent advances in imaging technologies have enabled 
non-invasive diagnosis of HCC with higher accuracy. 
However, small lesions, which could not be detected with 
imaging studies at the time of the establishment of the 
Milan criteria, can be seen on imaging studies with current 
technologies and can cause confusion regarding whether 
a patient meets the Milan criteria or not. A recent meta-
analysis including 22392 patients concluded that the size 
of the largest tumor and the total diameter of nodules were 
the best predictors of outcome, without sufficient evidence 
supporting the effect of the number of nodules on the 
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outcome of liver transplantation (237). Sugimachi et al. 
(238) also reported poor diagnostic accuracy of imaging for 
small (< 1 cm) HCCs and their limited effect on prognosis 
after liver transplantation. Therefore, lesions ≤ 10 mm 
or with atypical findings should not be used to make a 
decision for or against transplantation.
Before transplantation, HCC patients undergo tests for 
staging in addition to general whole-body examination 
for liver transplantation. In addition to dynamic contrast 
enhancement CT or MRI, extrahepatic staging should 
include CT of the chest, and CT or MRI of the abdomen and 
pelvis. Imaging of the brain, bone scintigraphy, and 18F-FDG 
PET-CT can be performed (239). 18F-FDG PET-CT can help 
characterizing the biology of HCC because PET-positive tumors 
more frequently display unfavorable histological features (e.g., 
high cellular dedifferentiation and microvascular invasion), 
resulting in poorer recurrence-free survival (RFS) after 
liver transplantation. There has been no specific study nor 
consensus on the optimal timing or modality of evaluation 
of patients on the waiting list to ensure whether they remain 
within the acceptability criteria for liver transplantation, 
although dynamic CT or MRI and AFP measurement at a 
3-month interval is commonly used (240).
Deceased Donor Liver Transplantation
Many patients are waiting for liver transplantation at any 
given time because of a shortage of deceased liver donors. 
A long waiting period is problematic for HCC patients. The 
American United Network for Organ Sharing introduced the 
Model for End-Stage Liver Disease (MELD) scoring system 
in order to decide the priority for liver transplantation. 
Patients with HCC involving a single nodule between 2 
and 5 cm or multinodular tumors (≤ 3 nodules ≤ 3 cm) 
are given the priority MELD score of 28 points, as well as 
10% additional points for every 3 months waiting for liver 
transplantation; thus, they have similar risks (241, 242). 
Meanwhile, the Korean National Organ Transplantation 
Management Center operates the Korean Network for Organ 
Sharing (KONOS) grading system, which gives no additional 
points to HCC patients. To solve this problem, Korea 
introduced the MELD score in June 2016. When fulfilling 
the Milan criteria, patients with a MELD score of 0 to 13 
receive an additional 4 points; patients with a MELD score 
of 14 to 20 also receive additional 5 points, but those with 
a MELD score of 21 or higher do not (243). Nevertheless, 
deceased donor liver transplantation (DDLT) in Korea is 
mostly performed when the MELD score is above 30. Further 
studies are needed determining the effect of the MELD score 
on HCC patients in Korea.
Bridging Therapy
Because it is difficult to predict the timing of liver 
transplantation in HCC patients, locoregional treatments, 
such as TACE, are commonly applied to those patients. The 
actuarial probability of dropout due to tumor progression 
while waiting for liver transplantation is reportedly between 
15% and 30% in 1 year (244, 245). Locoregional therapies 
have reduced the dropout rate to 0–25% (246-248). TACE or 
RFA can be performed to prevent tumor progression (246, 
247, 249-251). Markov-based cost-effectiveness analysis 
indicates benefits for neoadjuvant treatments when waiting 
times exceed 6 months (246). An AFP level increase > 
15 ng/mL/mo while waiting for liver transplantation is a 
relevant preoperative prognostic factor for poor OS and 
disease-free survival (252).
The effects of neoadjuvant treatments on survival after 
liver transplantation are difficult to assess. Many studies 
reported similar survival rates between treated and 
untreated individuals prior to transplantation (253-259). 
Patients who received locoregional treatments before liver 
transplantation in Organ Procurement and Transplantation 
Network/Scientific Registry of Transplant Recipients were 
more likely to achieve longer survival than those who 
did not, particularly those with longer waiting periods 
before transplantation (260). When the waiting period 
before liver transplantation is between 6 months and 18 
months, the HCC recurrence rate is low after transplantation 
(261). However, if the waiting period is prolonged, the 
possibility of HCC progression becomes higher, necessitating 
bridging therapy in such patients (246, 261, 262). In a 
recent multicenter study conducted in the United States, 
locoregional treatments did not affect the recurrence of HCC 
after transplantation in patients within the Milan criteria. 
Accordingly, bridging therapy in HCC patients within Milan 
criteria did not seem to positively affect HCC recurrence or 
patient survival (253). In this study, HCC recurrence after 
transplantation in patients with more than three sessions of 
locoregional treatment prior to transplantation developed 
twice as frequently than in patients with less than two 
sessions, regardless of the type of locoregional treatments 
(253). When complete tumor necrosis was confirmed 
by locoregional treatments in the explanted liver, the 
possibility of HCC recurrence after transplantation was very 
low (253).
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Downstaging
Regarding downstaging, there are no RCTs, large case-
control studies, or large well-designed cohort studies in 
which patients were treated consistently and properly 
followed up. Some prospective studies suggested that 
patients who achieved downstaging fulfilling the Milan 
or UCSF criteria following locoregional therapies achieved 
5-year survival outcomes similar to those within the Milan 
or UCSF criteria (251, 259, 263-267). Downstaging with 
TACE seems achievable in 24% to 63% of cases (268-270). 
Although downstaging is more effective if the tumor size 
is < 7 cm or tumor numbers are ≤ 3 (271), there is no clear 
upper limit for eligibility (272). Transarterial embolization 
(TARE) using yttrium-90 (90Y) for downstaging appears to 
have similar outcomes after transplantation compared with 
downstaging with conventional TACE (cTACE) (273, 274). 
However, more studies are required to demonstrate the 
efficacy of TARE for downstaging.
Living Donor Liver Transplantation
The number of DDLTs has been increasing in Korea recently 
due to changes in society’s perception of organ donation 
and the revision of laws to promote organ donation (275, 
276). However, living donor liver transplantation (LDLT) is 
the main type of liver transplantation in Korea because of 
deceased donor organ shortage. According to the KONOS 
regulation for registration and allocation in Korea, liver 
transplantation recipient candidates with HCC can gain 
higher priority on the waiting list. However, patients with 
HCC in Korea have a very low probability of receiving DDLT 
before tumor progression because most deceased donor 
livers are allocated to patients with a high MELD score 
(> 30). These findings suggest that DDLT is not a feasible 
treatment modality for HCC patients in Korea. Therefore, 
LDLT from a healthy donor has emerged as an alternative to 
DDLT as a treatment modality for HCC. In fact, a significant 
proportion of the liver transplantation recipients with HCC 
received transplantations from live donors in Korea. The 
comparative outcome of LDLT versus DDLT for patients with 
HCC is controversial. A meta-analysis of 633 LDLTs and 1232 
DDLTs indicates that LDLT is an acceptable option without 
compromising survival rates (277). However, the disease-
free survival rate is worse with LDLT than with DDLT (277). 
Another meta-analysis of 1310 patients who underwent LDLT 
and DDLT for HCC showed no difference in survival rate and 
disease-free survival (278). Patients undergoing LDLT have 
a short waiting time and are unlikely to drop out, whereas 
a dropout rate of 5% to 30% is reported in DDLT. Given that 
an intention-to-treat analysis can consider patients who 
dropped out of the waiting list, there was no difference 
in OS and disease-free survival between the two groups 
in liver transplantation according to the donation pattern 
on the intention-to-treat analysis (279, 280). The higher 
recurrence observed after LDLT in some reports is likely 
due to differences in tumor characteristics, pretransplant 
HCC management, and waiting time (281-283). In order 
to compare the outcomes of liver transplantation for HCC 
according to the type of graft, well-designed studies are 
needed to reflect bias and the effects of tumor biology.
In the DDLT program, the selection criteria have been 
set to maximize the efficacy-efficiency of donor organs. 
In contrast to DDLT, the indications for LDLT for HCC are 
decided based on the balance between donor risks and 
recipient benefits. Several eligibility criteria besides the 
Milan criteria for LDLTs have been adopted by many high-
volume LDLT centers. At Samsung Medical Center, patient 
selection according to tumor size < 5 cm and AFP < 400 
ng/mL without limitation of the tumor number expanded 
patient selection; 1-, 3-, and 5-year survival rates are 
reported to be 92.2%, 82.6%, and 79.9%, respectively 
(284). At Seoul National University Hospital, the 3-year 
survival rate is reported to be 86.2% if vascular invasion 
was absent in preoperative radiological studies and 
preoperative AFP was < 400 ng/mL (285). At Seoul Catholic 
Medical Center, LDLT is considered the preferred therapeutic 
option in patients with an AFP level < 100 ng/mL and a 
tumor diameter < 5 cm. The 5-year disease-free survival 
and OS rates after LDLT in all patients with HCC were 80.9% 
and 76.4%, respectively (286). At Asan Medical Center, 
patients with ≤ 6 HCCs ≤ 5 cm and without gross vascular 
invasion are considered eligible for liver transplantation; 
such patients had a 5-year survival rate of 81.6% (287). 
In the selection of HCC patients for liver transplantation, 
the University of Tokyo has adopted the 5-5 rule, that is, 
HCC ≤ 5 cm and ≤ 5 in number, and a RFS rate of 94% after 
liver transplantation was achieved (288). Kyoto University 
further extended the number of tumors to 10 with serum 
PIVKA-II levels ≤ 400 mAU/mL; the resultant 5-year survival 
rate was 86.7% (289). At Kyushu University, a 5-year survival 
rate of 82.7% was achieved in patients with HCCs ≤ 5 cm 
and serum PIVKA-II levels < 300 mAU/mL (290). In a study 
involving 49 centers and 653 patients in Japan, patients 
with HCCs beyond the Milan criteria but with serum AFP 
levels ≤ 200 ng/mL and serum PIVKA-II levels ≤ 100 mAU/mL 
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had a 5-year disease-free survival rate of 84.3% (291). Most 
of these expanded criteria were modified tumor size and 
number in the Milan criteria. However, the selection criteria 
have recently been amended to include biological markers 
such as AFP and PIVKA-II (292). European multicenter 
studies have shown that AFP-containing criteria better 
predict tumor recurrence after liver transplantation than 
criteria based on the number and size of tumors. There are 
reports that even if patients with HCC exceed the Milan 
criteria, they can achieve good results when fulfilling 
criteria including AFP (293, 294). LDLT has been proposed as 
an ideal setting for exploring expanded indications for HCC, 
considering a lack of graft allocation and priority policies. 
Moreover, the graft of a live donor is a personal gift. If the 
posttransplant outcomes of several eligible criteria beyond 
the Milan criteria for LDLTs are comparable with those within 
the Milan criteria, expanded indications can be accepted as 
long as the safety of the live donor is ensured.
The safety of the liver donor is of paramount importance 
in the LDLT. The outcomes of live donors from Korea 
are excellent (295-300). According to the Korean Organ 
Transplantation Registry study including 832 living liver 
donors, major complication (including bile leakage, biliary 
stricture, portal vein stricture, wound dehiscence, and 
pulmonary edema) rates were 1.9% and there was no 
mortality (301). The associated probabilities of death and 
life-threatening complications in LDLT for healthy donors 
are reported to be 0.2% to 0.3% and about 2%, respectively 
(302-305). Because of the complexity of the procedure, 
LDLT must be restricted to centers of excellence in hepatic 
surgery and liver transplantation to minimize donor risk and 
maximize recipient outcome. Careful attention should be 
given to the psychosocial wellbeing of live donors.
Immunosuppression after Liver Transplantation
Immunosuppressants like calcineurin inhibitors 
(cyclosporine and tacrolimus) and the mammalian target of 
rapamycin inhibitors (mTORi) (sirolimus and everolimus) are 
used for patients with HCC after liver transplantation (306). 
Recent studies have shown that the use of mTORi may be 
helpful for reducing recurrence and prolonging survival in 
HCC patients after liver transplantation, but further studies 
are needed (307).
[Recommendations]
1.  Liver transplantation is the first-line treatment for 
patients with single nodular HCC < 5 cm in diameter or 
3 or fewer nodules ≤ 3 cm in diameter (Milan criteria) 
who are not indicated for resection (A1).
2.  In liver transplantation candidates with HCC, 
locoregional therapies or TACE are recommended if the 
timing of transplantation is not predictable (B1).
3.  In patients beyond the Milan criteria, liver 
transplantation can be considered if successful 
downstaging to within Milan criteria can be achieved 
(C1).
4.  Expanded indications for liver transplantation can 
be considered in limited HCC cases beyond the 
Milan criteria without definitive vascular invasion or 
extrahepatic spread if other effective treatment options 
are not applicable (C2).
5.  Salvage transplantation can be indicated for recurrent 
HCC after resection according to the same criteria as 
for first-line transplantation (B1).
Locoregional Therapies
Locoregional therapies are widely performed as 
nonsurgical treatments for HCC because they are easy to 
perform and induce necrosis of tumor with minimal damage 
to the normal hepatic parenchyme. In a broader sense, 
TACE can be categorized as a locoregional therapy; only 
local ablation therapies will be discussed here, and TACE 
will be discussed in the following chapter. Among various 
kinds of locoregional therapies, RFA and percutaneous 
ethanol injection therapy (PEIT) are accepted as standard 
local therapies. In recent years, microwave ablation and 
cryoablation have been considered as effective locoregional 
treatments, while clinical trials are under way for other 
modalities, such as laser ablation therapy, intratumoral 
injection of radioactive holmium-166 microspheres, and 
high-intensity focused US.
The indications for locoregional therapies include patients 
with a single HCC nodule ≤ 5 cm or up to 3 nodules ≤ 3 
cm, although minor discrepancies exist across different 
investigators and studies. Efforts to apply locoregional 
treatments to larger HCCs have been made; however, the 
treatment outcomes are closely associated with tumor 
size. Contraindications for local therapies include corrected 
platelet count < 50 x 103/mm3 or prothrombin time 
prolongation (PT INR > 1.5).
Radiofrequency Ablation
RFA is the most widely used ablation technique for 
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HCC treatment. Very fast alternating currents (460 to 500 
kHz) flow in the vicinity of radiofrequency electrodes, 
inducing internal friction among molecules. The internal 
heat generated by the internal friction can evoke tissue 
necrosis. Exposure to temperatures higher than 60°C causes 
almost immediate protein denaturation and destruction of 
cell membranes followed by coagulative necrosis. Similar 
necrotic effects can also be obtained by maintaining 
the temperature from 45°C to 50°C for ≤ 3 minutes. The 
main advantage of RFA compared with PEIT is that fewer 
treatment sessions are required to achieve complete tumor 
necrosis. For HCC nodules ≤ 2 cm, RFA results in a higher 
complete tumor necrosis rate than PEIT (308-311). Most 
procedures are performed via a percutaneous approach; 
however, a laparoscopic or open surgical approach may be 
required in some instances.
The initial complete tumor necrosis rates, which were 
evaluated by CT or MRI within 1 day to 1 week after RFA, 
were reported to exceed 95%, and if RFA procedures are 
repeated for residual viable tumors, a complete tumor 
necrosis rate of almost 100% can be achieved (257, 310, 
312). However, the 3-year local tumor progression rate after 
RFA ranges widely from 0.9% to 21.4% (257, 312, 313). The 
local tumor recurrence rate at 10 years after RFA was 3.2% 
according to Shiina et al (257). However, Kim et al. (312) 
reported a local recurrence rate of 38.2% at 10 years after 
RFA and there is a big difference across institutions. The 
independent factors associated with OS after RFA include 
initial complete tumor necrosis, Child-Pugh score, number 
and size of tumors, and preoperative serum AFP level. RFA 
is the most effective treatment for patients with a single 
HCC smaller than 2 cm in diameter and Child-Pugh class A 
function. If the tumor is ideally located to perform RFA, 
the efficacy of RFA is comparable to that of hepatectomy. 
Hence, there are some reports which suggest that RFA 
should be considered as a primary treatment (136, 313).
The long-term survival outcomes of HCC patients after RFA 
is dependent on tumor size. For Child-Pugh class A patients 
with tumors < 2 cm, the 3- and 5-year OS rates after RFA 
are reported to be approximately 90% and 65% to 70%, 
respectively (257, 312, 313). Meanwhile, those for tumors 2 
to 5 cm are 65% to 75% and 50%, respectively (257, 312). 
The 10-year OS rate of Child-Pugh class A patients with a 
single HCC ≤ 3 cm is 41.3% (257).
Most of the studies comparing RFA with hepatic resection 
for HCC are not RCTs and even with RCTs, their sample size 
was too small to make a definite conclusion (314). Three 
RCTs, including the recently published study, showed no 
significant difference in survival rate between the two 
treatments (315-317). In RCTs that reported a difference 
in survival rates, the number of patients included in the 
single nodule < 3 cm group was small, and the one-year 
survival rate of RFA was 91%, which is substantially lower 
than the 100% survival rate for hepatic resection (318). A 
meta-analysis of RCTs showed that the 5-year survival and 
recurrence-free rates were significantly higher in the hepatic 
resection group of HCC patients within the Milan criteria 
(319); however, there was no significant difference in the 
survival rates between the two treatment groups for HCC 
of 3 cm or less (320). In another meta-analysis of patients 
with Child-Pugh class A HCC, there was no difference in 
5-year survival rates between the two treatment groups 
with tumor size < 3 cm (321). In a simulation study of 
patients with a single HCC less than 2 cm in diameter, long-
term survival rates were similar in the group treated with 
RFA as the primary treatment compared with the group who 
underwent hepatectomy (322). In a prospective controlled 
study recently published in Korea, there was no difference in 
the survival rates between hepatectomy and RFA. Although 
the disease-free survival rate was longer in the hepatectomy 
group (323), other non-RCTs have reported no significant 
difference in survival rates between hepatectomy and RFA 
in the treatment of HCC of 3 cm or less in diameter (324-
326). Hepatectomy had a higher incidence of complications 
and a longer hospital stay of 8 to 9 days on average (320).
For HCCs larger than 3 cm, the local recurrence rates 
after RFA are reported to range from 30% to 50% (312) and 
combined treatment with TACE and RFA can be considered 
for these tumors. When three or fewer HCCs of ≤ 3 cm in 
diameter were compared, the survival rate and recurrence 
rate were not significantly different between the combined 
treatment and RFA alone (327). In contrast, when the size 
of HCC ranges from 3 to 5 cm, the local recurrence rate 
and survival rate are better in the combined treatment 
group (328, 329). A meta-analysis of seven RCTs showed 
better survival in the combination treatment group than 
in the RFA monotherapy group; however, the subgroup 
comparison of tumors less than 3 cm in size showed no 
significant difference in survival rate between the combined 
treatments and RFA alone (330). In a meta-analysis of eight 
RCTs comparing RFA alone and combined treatment with 
RFA and TACE, combined treatment showed better survival 
and recurrence rates; however, there was no significant 
difference in the major complication rate between the 
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two groups (331, 332). Considering the results above, the 
combination of RFA and TACE in the treatment of HCC of 3 
to 5 cm showed a higher survival rate and lower recurrence 
rate than RFA alone and there was no significant difference 
in the incidence of complications between the two 
treatments.
Despite these favorable outcomes, RFA has some 
disadvantages. First, the risk of major adverse events is 
usually higher than that of PEIT, particularly when the 
tumors are located near the liver hilum or major abdominal 
organs, such as the colon. In addition, the heat sink effect 
may hinder effective transmission of heat energy to a tumor 
that is adjacent to relatively large intrahepatic vessels (311, 
333, 334) Sometimes, the risk of thermal injury to the 
adjacent abdominal organs can be overcome by inducing 
artificial ascites (335). Another major limitation of RFA is 
that HCC nodules < 2 cm may not be visible on conventional 
US. However, recent applications of US contrast agents and 
fusion imaging techniques have broadened the indications 
for RFA to such cases (336, 337).
The mortality rate due to procedure-related complications 
after RFA is reported to be 0.1–0.5%, and the major 
complication rate after RFA is less than 5% (313, 333, 334). 
Major complications include needle tract tumor seeding, 
hemoperitoneum, hemothorax, liver abscess, massive 
infarction of liver parenchyma, intestinal perforation, and 
pneumoperitoneum (257).
In conclusion, for HCCs that are within the Milan 
criteria, hepatic resection showed a lower recurrence rate 
than RFA and the rate of postoperative complications was 
significantly higher; however, further study is warranted to 
verify the difference in the survival rate. For single nodule 
HCCs of 3 cm or less in diameter, RFA has an equivalent 
survival rate, higher local recurrence rate, and lower 
complication rate than surgical resection. Therefore, it can 
be used instead of surgery for HCCs in an ideal location to 
perform RFA.
Percutaneous Ethanol Injection Therapy
PEIT was widely used in the treatment of HCC because 
it is relatively simple to perform and adverse reactions are 
infrequent. However, PEIT has been largely replaced by 
RFA, mainly because it has to be performed repetitively 
in contrast to RFA and it is difficult to obtain complete 
necrosis for tumors larger than 3 cm. The tumor necrosis 
rate of PEIT was reported to be 66–100% depending on the 
study (309-311, 338). Tumor size is important, and tumors 
less than 2 cm in diameter have more than a 90% tumor 
necrosis rate. However, as the tumor size increases, the 
necrosis rate decreases and the tumor necrosis rate is only 
50% for tumors 3 to 5 cm in size. Local tumor progression 
rates after PEIT range between 24% and 34%, although 
there is no consensus on the definition of local tumor 
progression (339-341). For patients with Child-Pugh class 
A function and a solitary HCC smaller than 2 cm, the 3- and 
5-year OS rates are 70% to 80% and ≥ 50%, respectively. 
For HCCs 2 to 3 cm in diameter, the 3-year OS rate ranges 
from 47% to 64% (309, 338).
Among the RCTs comparing RFA and PEIT in patients with 
HCC (309-311, 338, 342, 343), except those published in 
Italy (342, 343), RFA showed a significantly lower local 
recurrence rate and a higher survival rate. In particular, 
in a meta-analysis of four RCTs, the 3-year survival rate 
of RFA was significantly higher than that of PEIT (344-
347). However, there was no significant difference in the 
survival rate among the subgroups of HCCs less than 2 cm 
in diameter (346). These results suggest that the RFA group 
has a lower local recurrence rate and a higher survival rate 
than the PEIT group; however, further study is needed. In 
HCCs less than 2 cm in diameter, studies report a similar 
OS rate and PEIT can be considered if RFA is not feasible 
(348). PEIT can be performed to treat perivascular tumors 
to reduce the heat sink effect of RFA. However, the risk of 
biliary stricture is not avoided with PEIT if the tumors are 
located in the liver hilum (349, 350).
Microwave Ablation and Cryoablation
Recently, locoregional therapy for HCCs including 
microwave ablation and cryoablation is being more 
commonly used. The advantage of microwave ablation over 
RFA is that treatment efficacy is less affected by vessels 
located near the tumor and the ablation size is larger. 
In addition, effective ablation can be expected even for 
tissues with low electrical conductivity and an ablation 
temperature over 100°C can be achieved rapidly (351). 
Cryoablation has the advantage of monitoring the ablation 
extent because the ice ball shows a clear margin in an US 
scan, non-enhanced CT scan, or MRI. Moreover, cryoablation 
has less procedure-related pain (351, 352). However, 
cryoablation with a single probe generates a small ablation 
zone and thus, multiple probes are required to treat larger 
tumors.
In Child-Pugh class A and B HCC patients with a tumor 
size ≤ 5 cm or up to 3 nodules ≤ 3 cm, an RCT showed no 
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significant differences in the 1-, 3-, and 5-year OS rate or in 
the disease-free survival rate between RFA and microwave 
ablation (353). In chronic hepatitis patients with HCC size 
≤ 4 cm and up to 3 nodules, a multicenter randomized 
control study between RFA and cryoablation did not show a 
significantly different local tumor progression rate and OS 
rate over 20 months; however, its short follow-up period 
is a limitation (354). A meta-analysis study that aimed to 
compare RFA and other ablation techniques revealed that 
there is no significant difference in the OS rate and major 
complication rate between RFA and cryoablation (347). 
In Child-Pugh class A and B liver cirrhosis patients with 
one or two HCCs, a multicenter RCT showed no significant 
difference in the 1-, 3-, and 5-year OS rate, disease-free 
survival rate, and major complication rate between RFA and 
cryoablation (355).
In the limited RCTs and meta-analysis studies mentioned 
above, microwave ablation and cryoablation showed similar 
results in terms of the OS rate, recurrence rate, and major 
complication rate compared with RFA. Additional large-scale 
prospective RCTs are needed to confirm the difference in 
definitive treatment effects.
Other Locoregional Therapies
Clinical trials on other local therapies, such as high-
intensity focused ultrasound, laser ablation, and holmium 
injection therapy are under way. However, as there are 
few comparative studies with standard treatment, further 
technological developments and outcomes from the ongoing 
clinical trials are required to verify their efficacy in the 
management of HCC.
[Recommendations]
1.  RFA has the equivalent survival rate, a higher local 
tumor recurrence rate, and a lower complication rate 
than hepatic resection in patients with a single nodular 
HCC ≤ 3 cm in diameter (A1).
2.  RFA is superior to PEIT in terms of tumor necrosis effect 
and survival rate (A1). For HCCs ≤ 2 cm in diameter, 
PEIT can be considered if RFA is not feasible because 
the outcomes of both modalities are similar (A2).
3.  Combined therapy with RFA and TACE increases the 
survival rate for HCCs ranging from 3 to 5 cm in size 
that are not amenable to surgical resection compared 
with RFA alone (A2).
4.  In the treatment of HCC, microwave ablation and 
cryoablation are expected to produce comparable rates 
of survival, recurrence, and complications to those of 
RFA (B2).
TACE and Other Transarterial Therapies
The majority of HCCs are unresectable at the time of 
diagnosis because of portal hypertension, poor liver 
function, multiplicity of tumors, portal vein tumor invasion, 
inability to secure sufficient resection margin, old age, and 
severe comorbidities (356). TACE is the most commonly 
used nonsurgical treatment modality for these patients; 
meanwhile, tumor necrosis can be achieved by the combined 
effects of antitumor chemotherapy and selective ischemia 
of tumor tissue (275, 356, 357). In clinical practice, TACE 
is most widely utilized as a primary treatment modality for 
HCC (358). TACE can be classified as cTACE using lipiodol 
and drug-eluting bead TACE (DEB-TACE) (359, 360). It is 
important to note that TACE should be distinguished from 
TARE, which uses only embolic materials, and hepatic 
arterial infusion chemotherapy (HAIC), which uses only 
antitumor chemotherapeutic agents (361, 362).
Conventional TACE
The cTACE procedure involves an injection of a mixture 
of chemotherapeutic agents, such as doxorubicin, cisplatin, 
and mitomycin, with iodized oil into the feeding artery 
as an emulsion. This is followed by embolization of 
the same feeding artery using gelatin sponge particles, 
polyvinyl alcohol particles, or microspheres, which induce 
selective tumor ischemia. The most important technique 
for maximizing the antitumor effect and minimizing 
liver toxicity when performing TACE is to superselect the 
feeding arteries of tumors as distally as possible (363). 
Superselective chemoembolization of feeding arteries 
can significantly increase tumor necrosis and the local 
control rate (364, 365). In addition, cone-beam CT during 
chemoembolization can help detect tumors and tumor-
feeding arteries more precisely, thus resulting in a better 
therapeutic effect (366-368). Regarding the repetition 
strategy of TACE, on-demand repetitions to treat the 
residual or recurrent tumors can minimize the incidence of 
procedure-related liver toxicity, which is therefore preferable 
to on-schedule regular repetitions every 1 to 2 months.
Compared with best supportive case, several RCTs 
and meta-analyses confirm that TACE results in a more 
favorable tumor response, time to progression, and survival 
outcomes in patients with unresectable HCC (132, 369-371). 
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A prospective cohort study by the Japanese Liver Cancer 
Study Group reports that the 1-, 3-, 5-, and 7-year survival 
rates of 8510 patients who underwent TACE were 82%, 47%, 
26%, and 16%, respectively; for tumors larger than 5 cm, 
the 1-, 3-, and 5-year survival rates were 63%, 30%, and 
16%, respectively (372). In a prospective multicenter study 
performed in 27 Japanese and South Korean centers, the 
complete or partial remission rate according to the modified 
Response Evaluation Criteria in Solid Tumors (mRECIST) 
criteria was 73% and the 2-year OS rate was 75%; these 
figures are higher than those previously reported in the 
literature (373). These results are supported by a recent 
systematic review of 101 articles on cTACE published over the 
last 30 years, which showed that OS was 70.3% at 1 year, 
51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years 
(371). This outcome is similar to those of published RCTs.
Portal vein tumor invasion is found in approximately 
30% of HCC patients at initial diagnosis in Korea (357). 
According to the AASLD practice guidelines, systemic 
chemotherapy with sorafenib is the standard primary 
treatment for HCC with portal vein invasion (77). However, 
in practice, more aggressive treatment and various kinds 
of combined therapy are attempted (358) because the 
expected survival benefits are modest and there have been 
no study comparing sorafenib and locoregional treatment 
such as TACE (374). When TACE is performed for HCC 
patients with good hepatic function but portal vein tumor 
invasion, the risk of hepatic functional deterioration after 
TACE is reported to be acceptably low (375-378). The 1- 
and 3-year OS rates of such patients after repeated TACE 
range from 25% to 35% and 9% to 10%, respectively (372, 
379, 380). In patients with unresectable HCC with portal 
vein invasion, survival outcomes are more favorable in 
the TACE-treated group than in the supportive treatment 
group (380-382). Among HCC patients with portal vein 
invasion, patients with Child-Pugh class A function (375), 
tumors localized within the liver, tumors showing nodular 
growth (377, 379), or portal vein invasion not involving 
the main portal vein (378) showed a better prognosis. A 
recent retrospective study comparing standard sorafenib 
treatment, TACE, and TACE combined with radiation therapy 
in HCC patients with portal vein invasion showed that 
patients who underwent TACE combined with radiation 
therapy had longer median OS (383). Furthermore, there are 
retrospective studies showing that TACE is associated with 
survival gain, when intrahepatic HCC is treated with TACE in 
patients with extrahepatic metastasis (384-386). Recently, 
a Korean single center RCT reported that cTACE combined 
with radiation therapy significantly increased OS, the 
objective response rate (OSS), and time-to-progression (TTP) 
compared with sorafenib monotherapy in patients with HCC 
localized in the liver and portal vein invasion (387).
Local tumor response after cTACE can vary substantially 
according to the size and number of tumors, as well as 
patterns of tumor growth, such as tumor encapsulation 
and vascular invasion. The complete remission rate is 
quite low for large or multiple tumors despite multiple 
TACE sessions. However, in small tumors, complete tumor 
necrosis can be obtained in more than 50% of cases after 
superselective TACE (388). A prospective cohort study 
from Korea comparing surgical resection after primary 
TACE with TACE monotherapy published reports that the 
survival rates were similar between the two treatment 
groups with stage T3 disease. In addition, the survival 
rate of the TACE group with stage T1 and T2 disease was 
similar to that of the surgical resection group if iodized 
oil was compactly retained within the tumor (389). In a 
prospective cohort study of BCLC stage A disease patients 
in whom resection or ablation could not be performed, the 
1-month complete remission rate according to the mRECIST 
criteria was 67% and the 3-year OS rate was 80% (390). In 
another retrospective study comparing resection, RFA, and 
TACE as initial treatments for a single small HCC < 3 cm in 
diameter, the unadjusted 5-year OS rate of the TACE group 
was the lowest at 74.2%. However, after adjusting for 
liver functional status, thrombocytopenia, varix, etc., the 
differences in the survival outcomes among the groups did 
not reach statistical significance (324). Given the potential 
selection bias of the above-mentioned studies, TACE can be 
considered as an alternative treatment with curative intent 
when a patient refuses surgical treatment, or is at high risk 
for undergoing surgery, or HCC is not suitable for RFA.
The most common complication after TACE is post-
embolization syndrome (PES), which is a complex of 
symptoms, including fever, abdominal pain, nausea, and 
vomiting. Serious liver-related complications, including 
irreversible hepatic failure, hepatic infarction, abscess, and 
biliary injury can occur. Sepsis, pulmonary oil embolism, 
cholecystitis, gallbladder infarction, and gastrointestinal 
complications also occur (391). The frequency and 
severity of complications are related to tumor size, 
hepatic functional reserve, portal vein invasion, extent of 
chemoembolization, and dose of chemoembolic agents. 
According to a systematic review, the most common 
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complication after TACE was fever (57.8%), followed by liver 
enzyme abnormalities (52.0%), PES (47.7%), abdominal 
pain (42.5%), fatigue/malaise (39.9%), anorexia (38.0%), 
vomiting (34.2%), nausea (32.4%), and hepatological/bone 
marrow toxicity (28.6%). Hepatic failure occurred in only 1% 
of patients and no new or unexpected safety concerns were 
identified (371). Recently, the use of anti-inflammatory 
drugs, such as dexamethasone or parecoxib, to reduce post-
symptomatic syndrome before and after TACE has been 
reported in RCTs (392-394), and clinical application can be 
considered. However, caution needs to be taken because 
of the risk of adverse effects, such as worsening of viral 
hepatitis or diabetes.
In conclusion, cTACE is expected to have the best efficacy 
and safety in patients with nodular HCCs with preserved 
liver function and performance and no vascular invasion. 
A future RCT should evaluate the survival benefits of TACE 
for patients with unfavorable prognostic factors, such as a 
poor performance status, major portal vein tumor invasion, 
Child-Pugh class C function, and extrahepatic metastasis.
Drug-Eluting Bead TACE
Drug-eluting beads refer to microspheres loaded with 
high-dose doxorubicin, which can embolize tumor feeders. 
Embolization of the tumor feeders with microspheres has 
several benefits, such as tumor ischemia, higher intratumor 
drug concentration, and lower serum drug concentration due 
to the slow release of doxorubicin from the microspheres 
(395).
Prospective RCTs did not show a significant difference in 
the response rate, time-to-recurrence, and OS between the 
DEB-TACE group and cTACE group (396-398). A meta-analysis 
of four RCTs and eight observational studies also showed no 
significant difference in the 1-, 2-, and 3-year survival rates, 
response rate, and complication rate between two groups 
(399). However, pain after the procedure was less severe and 
frequent, and the length of hospital stay was also shorter by 
one day in the DEB-TACE group (400, 401).
A prospective multicenter registry including 152 Korean 
patients showed a complete remission and OSS of 40.1% 
and 91.4% at 1 month, and 43.0% and 55.4% at 6 months, 
respectively. There was no mortality related to liver abscess 
or other complications. In subgroup analysis, the OSS in 
the group with a tumor less than 2 cm tends to be lower 
than that in the group with a 2 to 5 cm tumor. This result 
suggests that the therapeutic effect of DEB-TACE may be 
lower than that of cTACE if the tumor is too small (402).
In conclusion, DEB-TACE has similar long-term survival, 
less PES, and shorter hospital stay than cTACE. Thus, further 
studies are needed to establish optimal indications for DEB-
TACE, considering cost-effectiveness and the trend that 
small tumors have lower response rates.
Transarterial Radioembolization Using 90Y Microspheres
TARE involves the injection of implantable radioactive 
microspheres into tumor-feeding arteries in order to expose 
the tumor to highly concentrated radiation while protecting 
the normal parenchyma. 90Y is the most commonly used 
radioisotope and emits high-energy and pure β-rays 
with a half-life of 64.2 hours, and mean and maximum 
tissue penetration of 2.5 and 11 mm, respectively. The 
microspheres available for 90Y infusion are 20 to 60 μm 
in diameter and are made of resin or glass. The small 
size of the injected microspheres and their concentration 
in hypervascular HCC minimize the embolic effect on 
surrounding tissue. Preprocedural angiography and 99mTc-
labeled macroaggregated albumin scans are required to 
determine the treatment site and radiation dose, and 
assess the degree of shunting to the lungs and any other 
extrahepatic organs. In particular, the lung dose achieved 
via hepatopulmonary shunt is important; thus, the radiation 
dose to be delivered should be adjusted so that the lung 
dose does not exceed 30 Gy per treatment and 50 Gy 
cumulatively (403).
In a prospective single-arm phase II study of 52 patients 
with intermediate or advanced HCC treated with TARE, the 
objective tumor response rate (i.e., the complete or partial 
remission rate) was 40.4%, and the median survival period 
was 15 months (404). In a recent prospective multicenter 
study performed in Korea on 40 HCC patients with BCLC 
stage B or C disease, the 3-month tumor response rate was 
57.5% and the 3-year OS rate was 75% (405). However, 
two recent phase III RCTs on advanced HCC failed to 
show survival gain compared with sorafenib, although 
TARE showed a higher response rate and lower toxicity 
(406, 407). The results of small RCTs and meta-analyses 
comparing TARE with cTACE or DEB-TACE differ between 
studies; however, the survival rate, OS, and safety were not 
significantly different between the two treatments, and TTP 
of TARE tends to be longer (408-413).
The most frequent adverse effect after TARE is 
transient fatigue. However, TARE less frequently causes 
postembolization syndrome because the embolic effect is 
minimal, and it can be safely performed even in patients 
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with portal vein tumor invasion. Elevated serum bilirubin 
levels occur in 20% of patients, and the mortality rate 
within 1-month ranges from 0% to 3% (404, 414, 415). 
Severe complications, such as radiation pneumonitis and 
gastroduodenal ulcer, can occur in the event of inadvertent 
embolization into the extrahepatic organs. Therefore, 90Y 
TARE requires meticulous treatment planning and operator 
experience. 
In summary, TARE has not shown survival gain compared 
with standard treatment, including sorafenib and TACE in 
RCTs, until now. However, TARE can minimize PES and is 
expected to enhance the response rate and prolong TTP 
compared with TACE; thus, TARE can be an alternative 
treatment to TACE in select patients, considering cost-
effectiveness. An ongoing RCT on combined treatment of 
TARE and sorafenib (NCT01556490) is under way.
[Recommendations]
1.  cTACE is recommended for HCC patients with a good 
performance status without major vascular invasion 
or extrahepatic spread who are ineligible for surgical 
resection, liver transplantation, RFA, or PEIT (A1).
2.  cTACE should be performed through tumor-feeding 
vessels using selective/superselective techniques to 
maximize antitumor activity and minimize hepatic 
damage (B1).
3.  In cases of HCC with portal vein invasion, cTACE alone 
(B2) or combined therapy of cTACE and external beam 
radiation therapy (EBRT) (B1) can be considered for 
patients with localized tumors and well-preserved liver 
function.
4.  DEB-TACE has similar therapeutic efficacy and results 
in less PES compared with cTACE (B2).
5.  TARE can be considered as an alternative treatment to 
TACE when patients have preserved liver function and 
reduction of PES is required (B2).
External-Beam Radiation Therapy
EBRT for the treatment of HCC is commonly used for 
lesions that are surgically unresectable and not amendable 
with other local modalities (416). Child-Pugh class A or B7 
are liver functional criteria for EBRT. The reported overall 
response rates and median survival after EBRT are 40% 
to 90% and 10 to 25 months, respectively (417). EBRT 
requires computerized radiation therapy planning by CT, and 
the liver volume receiving ≤ 30 Gy must be ≥ 40% of the 
total liver volume for patients with Child-Pugh class of A 
or B7 function in three-dimensional radiotherapy planning-
based dose-volume analysis (418). For hypofractionated 
EBRT consisting of ≤ 10 fractions, the normal liver volume 
receiving < 15 Gy must be ≥ 700 mL and the dose to the 
normal liver volume excluding the tumor should be limited 
to ≤ 28 Gy (corrected to 2 Gy per fraction-equivalent dose) 
(419, 420). For patients with a Child-Pugh score of B8 or 
higher, it is necessary to apply more stringent dose-volume 
constraints than for patients with Child-Pugh class of A or 
B7 (421-423).
Hypofractionated radiation therapy, stereotactic body 
radiotherapy, or particle therapy for HCC resulted in 3-year 
local control and OS rates of 70% to 100% and 45% to 
80%, and 5-year local control and OS rates of 69% to 
96% and 40% to 70%, respectively (424-449). A meta-
analysis reported that the use of TACE in combination with 
EBRT significantly improved the tumor response, 1-, and 
3-year survival rates compared with TACE monotherapy 
(450). One study reported that when EBRT was used for 
patients unsuitable for TACE owing to severe tumor-induced 
arteriovenous shunts, 20% of these patients were able to 
undergo TACE successfully after radiation therapy-induced 
vascular occlusion (451). Moreover, the addition of EBRT for 
HCC after incomplete TACE resulted in a complete response 
rate of 20% to 25% (452, 453). The sequential combination 
of EBRT 2 weeks after TACE may be complicated by liver 
dysfunction; however, Common Terminology Criteria of 
Adverse Events grade ≥ 3 liver dysfunction was reported in 
only 2.5% of all patients (454).
EBRT can be performed safely for HCC patients with 
macrovascular invasion by the tumor. The reported overall 
response rates and median survival after EBRT for HCC 
patients with major vascular invasion are 30% to 83% and 
7 to 34.4 months, respectively (429, 432, 438, 451, 455-
472). Furthermore, combined treatment of TACE and EBRT 
for HCC patients with inferior vena cava invasion resulted 
in a superior median survival of 11.7 months compared 
with the historical cohort treated with TACE alone (460). 
In a Korean multicenter retrospective cohort analysis, 67% 
of patients who received EBRT for HCC with portal vein 
invasion received combined treatment with TACE or HAIC 
(473). A recent meta-analysis reported that combination 
therapy of TACE or HAIC and EBRT for HCC patients with 
portal vein invasion significantly improved the objective 
response and OS rates compared with TACE or HAIC 
monotherapy (474). In retrospective series (383, 475, 476) 
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and a recent prospective RCT (387), combination therapy 
of TACE and EBRT for HCC patients with portal vein invasion 
significantly improved survival compared with sorafenib 
monotherapy.
TACE or HAIC combined with EBRT for locally advanced 
HCC resulted in a median survival of 13 to 20 months (431, 
457, 477). Surgical resection can be considered for patients 
with locally advanced HCC who achieved downstaging with 
EBRT, which was reported to be safe and effective (478-480). 
In addition, EBRT can be considered as a bridging treatment 
for patients awaiting liver transplantation (481-483), or 
as a second-line treatment for recurrent HCC after surgical 
resection, RFA, PEIT, or TACE (416, 425, 484-487).
EBRT is also effective for relieving symptoms, such as 
cancer pain (417, 488, 489). In HCC patients with jaundice 
due to malignant biliary obstructions, EBRT successfully 
reduced tumor size with alleviation of symptoms; 
accordingly, EBRT is also expected to improve survival in 
these patients (490, 491). In patients with abdominal 
lymph node metastases, EBRT results in response rates of 
approximately 75% to 95% with improved survival (492-
498). In patients with adrenal metastases, EBRT achieved 
disease control in more than 90% (499). In addition, 
EBRT for lung metastases resulted in response rates from 
65% to 75% while symptom relief was achieved in 90% 
of symptomatic patients (496, 500). EBRT is reported to 
relieve pain in 75% to 99% of patients with symptomatic 
bone metastases (501-507). Moreover, in a previous study, 
EBRT for spinal cord compression from vertebral metastases 
is reported to prevent neurologic dysfunction in 63% to 
83% of patients (508-510). In case of brain metastases 
from HCC, patients can receive EBRT to relieve symptoms 
(511-513).
[Recommendations]
1.  EBRT can be considered for HCC patients ineligible for 
surgical resection, liver transplantation, other local 
modalities, or TACE (C1).
2.  EBRT is feasible in HCC patients if their liver function 
is Child-Pugh class A or B7 and the irradiated total 
liver volume receiving ≤ 30 Gy is ≥ 40% (B1).
3.  EBRT can be performed for HCC patients who exhibit an 
incomplete response to TACE (B2).
4.  EBRT can be performed for HCC patients with portal 
vein invasion when the dose-volume criteria in 
Recommendation 2 are met (B2).
5.  EBRT can be performed to alleviate symptoms caused 
by metastases (B1).
6.  EBRT can be considered for HCC patients who have 
recurrent or refractory disease after local therapy (C1).
Systemic Therapies
Systemic therapy refers to any type of drug treatment that 
travels the bloodstream to reach cancer cells throughout 
the body. Systemic therapies include conventional cytotoxic 
chemotherapeutic agents, as well as molecularly targeted 
therapy (MTT) which targets the intracellular signals 
involved in the growth and metastasis of cancer cells, 
and immunotherapy which stimulates the host immune 
system to fight the cancer cells. Currently, conventional 
chemotherapy, MTT agents, and immune checkpoint 
inhibitors (a type of cancer immunotherapy) are utilized as 
systemic therapies for HCC.
Sorafenib
Sorafenib is a multi-kinase inhibitor that targets vascular 
endothelial growth factor receptor-2 (VEGFR-2), platelet-
derived growth factor receptor (PDGFR), Raf-1, and 
c-kit. Sorafenib was the first MTT agent approved for the 
treatment of advanced HCC. In the SHARP study, a global 
phase III trial, the median survival of HCC patients with 
portal vein tumor invasion or extrahepatic metastasis 
treated with sorafenib was 10.7 months, which was 
significantly longer than the 7.9-month survival of patients 
who received a placebo (HR, 0.69; 95% CI, 0.55 to 0.87; 
p = 0.0006) (514). The TTP in the sorafenib group was 5.5 
months, which was also significantly longer than the 2.8 
months in the control group. In the Asia-Pacific phase III 
trial that included Korean patients with unresectable HCC, 
patients who received sorafenib had a significantly longer 
median survival (6.5 months) than patients in the control 
group (4.2 months: HR, 0.68; 95% CI, 0.50 to 0.93; p = 
0.01) (515). Five randomized controlled phase III trials 
and one phase II trial tested novel MTT agents in which all 
patients in the control group were treated with sorafenib; 
the median survival of patients treated with sorafenib was 
consistently reported to be approximately 10 months (range, 
8.4 to 12.3 months) (516-520).
The two previously mentioned phase III trials for 
sorafenib (the SHARP and Asia-Pacific trials) recruited 
HCC patients with Child-Pugh class A liver function and an 
ECOG performance status of 0–2. In real-world practice, 
the safety and efficacy of sorafenib are reported to be 
1073
KLCA and NCC Korea: 2018 Practice Guidelines for HCC
https://doi.org/10.3348/kjr.2019.0140kjronline.org
comparable between Child-Pugh class A and B function 
patients (521-523); however, the presence of ascites and 
a higher Child-Pugh score are significantly associated with 
the poor prognosis of sorafenib-treated patients (524). The 
GIDEON study, which was a large-scale observational study 
involving 3171 patients from 39 nations who were treated 
with sorafenib, reported that overall adverse events and 
treatment-related adverse events were not significantly 
different according to Child-Pugh class. However, serious 
adverse events (SAEs) were significantly more frequent 
in Child-Pugh B patients than in Child-Pugh A patients. 
Moreover, within Child-Pugh B patients, Child-Pugh B8–9 
patients experienced SAEs more frequently than Child-
Pugh B7 patients. Median OS was different according to 
Child-Pugh class: 13.6 months for class A, 6.2 months 
for B7, 4.8 months for B8, and 3.7 months for B9 (17). 
Although sorafenib can be considered for patients with 
poor liver function (i.e., Child-Pugh B7 patients), further 
interventional study is warranted to determine the optimal 
use of sorafenib in these patients.
Since sorafenib’s introduction to clinical practice, all of 
the clinical trials that evaluated treatment outcomes of 
combination treatment with TACE plus sorafenib or other 
MTT agents to improve OS have failed to show gains in OS 
compared with sorafenib monotherapy (525). Recently, 
a Korean randomized controlled multicenter phase III 
trial reported that sorafenib with concurrent cTACE failed 
to significantly prolong OS of advanced HCC patients 
compared with sorafenib alone (median OS, 12.8 months 
vs. 10.8 months; HR, 0.91; 95% CI, 0.69 to 1.21; p = 
0.290). However, combination treatment with sorafenib 
and concurrent cTACE significantly improved the secondary 
outcomes of progression-free survival (PFS), TTP, and tumor 
response rate compared with sorafenib alone. Post-hoc 
analysis showed that OS was significantly longer in the 
combination treatment group than in the sorafenib alone 
group if the patients received more than two sessions of 
cTACE (median OS, 18.6 months vs. 10.8 months; HR, 0.58; 
95% CI, 0.40 to 0.82; p = 0.006) (526).
The most common adverse event related to sorafenib 
treatment is hand-foot skin reaction (HFSR); other common 
adverse events include fatigue, skin rash, hypertension, 
hoarseness, anorexia, weight loss, constipation, and 
alopecia. HFSR tends to resolve spontaneously after 
3 months of treatment; therefore, it is important to 
continue therapy with patient education and proper 
management. For example, creams containing urea may be 
helpful for preventing dryness of the hands and feet. It is 
recommended that patients remove thick calluses, wear 
comfortable shoes with cushioning, avoid bathing with hot 
water, and take analgesics, if necessary, to mitigate and 
alleviate the symptoms associated with HFSR (527). Since 
HFSR and hypertension have been reported as potential 
surrogate predictors of a good response to sorafenib, the 
management of adverse events needs to be emphasized to 
clinicians and patients (528).
Second-line treatments for patients who experience tumor 
progression with sorafenib include regorafenib, nivolumab, 
cabozantinib, and ramucirumab. These agents have proven 
efficacy in clinical trials, which will be described in the 
“Secon-dline Therapy after Sorafenib Failure” section.
Lenvatinib
Lenvatinib is an oral multi-kinase inhibitor targeting 
VEGFR-1/2/3, fibroblast growth factor receptor (FGFR)-
1/2/3/4, PDGFR-α, ret proto-oncogene (RET), and c-kit. 
In a recently published randomized controlled non-
inferiority phase III trial, lenvatinib demonstrated non-
inferior OS compared with sorafenib for advanced HCC 
patients with a tumor occupying less than 50% of the 
liver and no bile duct or main portal vein invasion (HR, 
0.92; 95% CI, 0.79 to 1.06) (519). This was the first OS 
success reported in HCC in the 10 years since sorafenib’s 
initial success. Median OS was 13.6 months (95% CI, 12.1 
to 14.9 months) for the lenvatinib group and 12.3 months 
(95% CI, 10.4 to 13.9 months) for the sorafenib group. 
PFS and TTP, both secondary outcomes, were significantly 
longer in the lenvatinib group than in the sorafenib group 
(PFS: 7.4 months vs. 3.7 months; HR, 0.66; 95% CI, 0.57 
to 0.77, p < 0.00001; TTP: 8.9 months vs. 3.7 months; HR, 
0.63, 95% CI, 0.53 to 0.73; p < 0.0001). In the masked 
independent imaging review according to RECIST 1.1, the 
ORR was significantly higher in the lenvatinib group (18.8%: 
complete response < 1%, partial response 18%) than in the 
sorafenib group (6.5%: complete response < 1%, partial 
response 6%) (OR, 3.34; 95% CI, 2.17 to 5.14; p < 0.0001).
SAEs were significantly more frequent in the lenvatinib 
group than in the sorafenib group (43% vs. 30%: OR, 
2.34; 95% CI, 1.80 to 3.04; p < 0.0001) (519). HFSR was 
less frequent in the lenvatinib group (27%) than in the 
sorafenib group (54%), and hypertension was more frequent 
in the lenvatinib group (42%) than in the sorafenib group 
(30%). Other adverse events frequently observed in the 
lenvatinib group were diarrhea (39%), anorexia (34%), 
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weight loss (31%), fatigue (30%), proteinuria (25%), and 
hypothyroidism (16%). 
The efficacy and safety of lenvatinib for Child-Pugh B 
patients has not been evaluated. Additionally, no second-
line treatment has been established for patients who 
experience tumor progression with lenvatinib treatment.
Nivolumab
Nivolumab is an immune checkpoint inhibitor that 
disrupts programmed cell death receptor-1 (PD-1). It is a 
recombinant human IgG4 monoclonal antibody that can 
be administered intravenously. The CheckMate-040 trial 
(ClinicalTrials.gov ID: NCT01658878), a non-comparative 
phase I/II trial that evaluated the efficacy of nivolumab 
for patients with advanced HCC, demonstrated an overall 
ORR of 20% (complete response 1%, partial response 18%) 
and a duration of response of 9.9 months (529). In a 
subgroup analysis involving sorafenib-naïve patients, the 
ORR was 20% (complete response 1.3%, partial response 
18.8%) according to RECIST 1.1, which was similar to the 
ORR of the sorafenib-experienced group. Since the median 
OS was as long as 28.6 months (530), nivolumab may 
have a promising role as a first-line treatment. Currently, a 
randomized controlled multicenter phase III trial comparing 
nivolumab and sorafenib as first-line treatment for advanced 
HCC (CheckMate-459, Clinical- Trial.gov ID: NCT02576509) 
is ongoing, and the results will be noteworthy.
[Recommendations]
1.  Sorafenib is recommended for HCC patients who have 
regional lymph node involvement, distant extrahepatic 
metastasis, or intrahepatic vascular invasion, or 
patients who experienced tumor progression with 
other treatments if they have very well-preserved liver 
function (Child-Pugh class A) and a good performance 
status (ECOG 0–1) (A1). For patients who are indicated 
for sorafenib treatment, combination treatment with 
sorafenib and cTACE is generally not recommended (A1).
2.  Lenvatinib is recommended for HCC patients who have 
regional lymph node involvement, distant extrahepatic 
metastasis, or portal vein tumor invasion (not 
extending to the main portal vein) or patients who 
experienced tumor progression with other treatments, 
if they have a tumor occupying less than 50% of the 
liver, very well-preserved liver function (Child-Pugh 
class A), and a good performance status (ECOG 0–1) 
(A2).
3.  Sorafenib is considered for HCC patients with liver 
function classified as Child-Pugh score B7 and a 
good performance status if the conditions listed in 
Recommendation 1 are satisfied (C1).
Adjuvant Therapy
Adjuvant therapy usually refers to an additional treatment 
after definitive or curative therapy to prevent recurrence. 
As the 5-year recurrence rate even after curative resection 
for HCC is very high at 50% to 70% (154, 531, 532), an 
effective adjuvant therapy is urgently required. Although 
many studies for adjuvant therapy after curative therapy in 
HCC through TACE (533), 131I infusion via the hepatic artery 
(534), vitamin K2 (535), and vitamin A analogue (536) have 
been performed, there is still no proven clinical significance 
(77). Cytotoxic systemic chemotherapy (537) and sorafenib 
(538) also have no clinical evidence for adjuvant therapy.
After a Japanese study reported that adjuvant therapy of 
cytokine induced killer (CIK) cells reduced the 3-year HCC 
recurrence rate by up to 15% in CIK cell-treated patients 
compared with control patients (539). Several prospective 
RCTs have been conducted (540-544). In a recent Korean 
phase III RCT (541), adjuvant therapy with CIK cells 
significantly improved RFS (HR, 0.63; 95% CI, 0.43 to 0.94) 
and OS (HR, 0.21; 95% CI, 0.06 to 0.75) in AJCC stage I 
or II HCC patients after curative resection or local ablative 
therapy (RFA or PEI). An extended follow-up study (median, 
68.5 months) also showed a sustained improvement in 
both RFS (HR, 0.67; 95% CI, 0.48 to 0.94; p = 0.009) and 
OS (HR, 0.67; 95% CI, 0.48 to 0.94; p = 0.009) and the 
5-year RFS rate was 44.8% in the CIK cell group and 33.1% 
in the control group (545). In a phase III RCT in China, 
CIK cell treatment showed significantly prolonged time-to-
recurrence (13.6 months in the CIK group and 7.8 months 
in the control group, p = 0.01). However, in that study, 
there was no statistically significant difference in either RFS 
or OS (540). In a meta-analysis involving RCTs of adjuvant 
therapy with CIK cells in HCC patients after curative 
treatment, adjuvant CIK cell therapy significantly improved 
RFS and OS up to 3 years (546).
Even for resectable HCC, TACE can be applied prior to 
resection as a neoadjuvant therapy. However, there is no 
evidence that TACE followed by resection increases disease-
free survival compared with resection only in resectable HCC 
(547).
1075
KLCA and NCC Korea: 2018 Practice Guidelines for HCC
https://doi.org/10.3348/kjr.2019.0140kjronline.org
[Recommendations]
1.  Patients with AJCC I, II stage HCC could be considered 
for adjuvant immunotherapy with CIK after curative 
resection or local ablation therapy (RFA or PEI) (B2).
2.  Adjuvant therapy with TACE, sorafenib, or cytotoxic 
chemotherapy is not recommended for HCC patients 
treated with curative therapy (B1).
Second-Line Treatment after Failure of First 
Treatment
The second-line treatment to improve survival in HCC that 
has recurred after liver resection, liver transplantation, and 
RFA is very important; however, a prospective comparative 
study comparing the guidelines and each treatment has not 
been conducted except for second-line systemic treatment. 
Nevertheless, in actual clinical practice, the second-
line treatment after the first treatment failure of HCC is 
very common due to the nature of the HCC. Therefore, 
the current evidence for second-line treatment after first 
treatment failure is described in this guideline.
Treatment of Intrahepatic Metastasis after Hepatic 
Resection
The rate of postoperative recurrence with intrahepatic 
metastasis owing to local dissemination or de novo 
carcinogenesis is about 50% to 70% at 5 years after 
surgical resection. Recurrence of the tumor with 
intrahepatic metastasis usually presents as intrahepatic 
multiple recurrence. In such cases, it is often impossible to 
repeat curative treatment and the risk of recurrence after 
treatment is high. In contrast, de novo recurrence can be 
the target of curative re-operation or local treatment (154, 
169, 531, 548-550). Typically, recurrence within 2 years 
after surgery is classified as early recurrence and recurrence 
after 2 years is classified as late recurrence (154, 551). 
The risk factors for recurrence can be divided into tumor-
related factors and underlying liver disease-related factors. 
Tumor-related risk factors include tumor size, number, 
degree of differentiation, vascular involvement, serum AFP 
level (elevated before surgery), lack of adequate resection 
margin, and non-anatomical resection, which are mainly 
associated with early recurrence (154, 158, 548, 549, 
552, 553). The risk factors for underlying liver disease 
are high serum HBV DNA levels before and after surgery 
for chronic hepatitis B (159, 554-556) and persistent 
active inflammation and degree of hepatic fibrosis for 
chronic hepatitis C (556, 557); these are associated with 
late recurrence. According to many retrospective studies, 
recurrent hepatectomy for intrahepatic recurrence has been 
recognized as an effective treatment with a 5-year OS rate 
of 52% (range, 22% to 83%) (152, 552, 558). Salvage liver 
transplantation is one of the most effective treatments to 
increase disease-free survival and OS rates compared with 
repeated hepatectomy, but the occurrence of complications 
related to surgery (549) is significantly higher (559). 
However, the patients who undergo repeated resection 
are limited in clinical practice because they have a small 
residual liver parenchyma after resection and are at risk 
of recurrence (560). Liver transplantation is more limited 
because of the shortage of donors. For recurrent HCC which 
is not indicated for repeated hepatic resection, nonsurgical 
local treatments such as RFA and TACE can be applied. RFA 
has been extensively performed as a minimally invasive 
treatment for small relapsing HCC (561, 562). TACE is the 
most widely used treatment for multiple HCC recurrences 
(562-564). The meta-analysis (565-569) comparing the 
effects of each of the abovementioned treatments revealed 
that there was no difference in survival benefit among 
the treatment modalities for recurred tumors after surgery. 
Therefore, considering the remaining liver function and the 
location and number of recurrences, appropriate treatment 
options should be selected.
Treatment of Intrahepatic Metastasis after RFA
Local recurrence was reported to be higher in patients 
who underwent local treatment, such as RFA or PEI (318, 
570). Local recurrence is defined as recurrence of the tumor 
at the treatment site or margins after curative treatment. 
Local recurrence rates up to 2 years after treatment are 
reportedly 2% to 18% for RFA and 11% to 45% for PEI 
(309-311, 338, 342). For PEI, the diffusion of injected 
ethanol may be blocked by the fibrous septum or tumor 
capsule, resulting in a decreased therapeutic effect. 
Specifically, since the local recurrence rate was reported to 
be as high as 43% after percutaneous injection for lesions 
larger than 3 cm in diameter, special caution is needed (571).
A large-scale retrospective study at a single institution 
in South Korea reported that the 5- and 10-year cumulative 
recurrence rates were 73.1% and 88.5%, respectively, after 
RFA for a single, ≤ 5 cm-sized tumor or three ≤ 3 cm-sized 
nodules (312). RFA showed the best therapeutic efficacy 
for patients with small single nodular HCC (especially 
HCC of ≤ 2 cm) and well-preserved liver function with a 
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5-year survival rate of 70% (313). Since repeated RFA 
for recurred HCC after RFA can improve survival if it 
achieves a complete response, the early detection of local 
recurrence is important (572). Surgical treatment, such 
as surgical resection and salvage liver transplantation, for 
recurrent cancer after RFA showed a similar therapeutic 
effect compared with repeated RFA (573, 574). If surgical 
treatment or RFA is not feasible, TACE can be applied (575).
Treatment of Recurrent HCC after Liver Transplantation
The recurrence rate has been reported to range from 
8% to 20% even after liver transplantation for HCC 
within the Milan criteria (576). Due to the influence 
of immunosuppression after liver transplantation, the 
prognosis of recurrent HCC after LT is poor. The median OS 
after diagnosis of recurrence is less than 12 months, and 
5-year survival rates are only 22% (576, 577). Among 119 
patients who underwent liver transplantation for HCC, HCC 
recurrence occurred in 15 patients (13.4%) during a median 
17.2 months of follow-up, and intrahepatic recurrence was 
the most common (578). In another study of 857 patients 
who underwent liver transplantation for HCC, 106 patients 
(12.4%) experienced HCC recurrence during a median 
15.8 months of follow-up after liver transplantation, and 
the median OS after recurrence was 10.6 months. The 
sites of recurrence were the lung (55.7%), liver (37.8%), 
abdominal cavity (37.7%), and bone (25.5%) (579). Since 
the prognosis of patients with recurrent HCC after liver 
transplantation is associated with treatment modality 
after recurrence, as well as to time-to-recurrence, multiple 
organ involvement, pre-liver transplantation HCC stage, and 
pathological stage of the explanted liver, an individualized 
approach might be required to improve the outcomes (580).
Survival rates can be increased if curative therapy is 
applicable even in patients with recurred HCC after liver 
transplantation. Among 121 patients who had recurrent HCC 
after liver transplantation for HCC, 38 (31.4%) underwent 
resection or locoregional therapies, 51 patients (42.1%) 
received palliative therapies, and the other 32 (26.4%) 
received supportive therapy (581). The median OS in 
patients who underwent curative therapies was significantly 
longer than that in patients who underwent other therapies. 
A Japanese study analyzed 17 patients who experienced HCC 
recurrence among 101 patients who had undergone LDLT 
between 1996 and 2007. Among the included patients, nine 
underwent surgical treatments, including six with hepatic 
resection, 10 with lung metastatectomy, and three with 
lymph node dissection, and the remaining eight patients 
received nonsurgical treatment. The 1-, 3-, and 5-year 
survival rates of the surgical treatment group were 100%, 
87.5%, and 87.5%, respectively, while those in non-surgical 
treatment group were 50%, 12.5%, and 0%, respectively, 
which reached statistical respectively (582).
For recurrent HCC confined to the liver after liver 
transplantation which is not feasible for surgical resection, 
RFA can result in a good outcome. Among 78 patients who 
experienced HCC recurrence after liver transplantation, 
surgical resection, RFA, and supportive care were performed 
for 15, 11, and 52 patients, respectively. The 1-, 3-, and 
5-year survival rates were in 92%, 51%, and 35% in the 
resection group, respectively, and 87%, 51%, and 28% 
in the RFA group, respectively. There was no significant 
difference in survival between the two groups (p = 0.879). 
There was also no difference of RFS between the two 
groups: the 1-, 3-, 5-year RFS rates were 83%, 16%, 16% in 
the resection group, respectively, and 76%, 22%, and 0% in 
the RFA group, respectively (p = 0.745) (583).
Because a significant proportion of recurrent HCC 
patients have multiple intrahepatic lesions or extrahepatic 
metastasis after liver transplantation, it is infrequently 
possible to apply curative treatment, such as resection or 
RFA. There have been few reports on the efficacy and safety 
of TACE for post-liver transplantation recurrent HCC. In a 
study of 14 patients with intrahepatic and extrahepatic 
recurrence after liver transplantation, the rates of partial 
response, stable disease, and progressive disease were 57%, 
28%, and 14%, respectively. The 6-, 12-, and 24-month 
survival rates in patients who underwent TACE were 64.3%, 
50%, and 22.2%, respectively, while the rates were 35.7%, 
21.4%, and 10.7% in patients who received systemic 
chemotherapy, respectively (p = 0.034) (584). The Child-
Pugh score was not elevated after TACE for recurrent HCC 
after liver transplantation, and there was no SAE. The 
severity of PES was also comparable with that in patients 
who did not undergo liver transplantation. In a study from 
Taiwan, the median OS was 6.6 months (range, 0.3–12.7 
months) and the 1-year survival rate was 12.5% in 11 
patients who underwent TACE for recurrent intrahepatic HCC 
after liver transplantation (585).
Sorafenib is indicated in patients with widespread 
recurrence after liver transplantation for whom resection, 
RFA, or TACE is not feasible, or in patients with progressive 
disease after locoregional therapy. However, there has been 
no well-designed RCT to validate the efficacy and safety 
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of sorafenib in those patients. In a case-control study of 
39 patients with recurrent HCC after liver transplantation, 
24 patients received best supportive care and 15 received 
sorafenib. The median OS after tumor recurrence was 
significantly longer in the sorafenib group (21.3 months) 
than in the best supportive care group (11.8 months) 
(HR, 5.2; p = 0.0009) (586). There was no SAE associated 
with sorafenib administration. However, another study 
reported a higher risk of sorafenib-related toxicity in 
patients with liver transplantation (587). A case report 
demonstrated increased mortality due to gastrointestinal 
bleeding in patients who received combination therapy with 
sorafenib and everolimus, an mTOR inhibitor, to enhance 
antitumor activity (588). In another study including 34 
patients with post-liver transplantation recurrent HCC, 17 
received sorafenib treatment and the remaining 17 received 
supportive care. The 3- and 12-month survival rates were 
100% and 62% in the sorafenib group, respectively, 
which were significantly higher than the 73% and 23%, 
respectively, in patients receiving supportive care. The 
common adverse events were diarrhea (18%), elevation of 
transaminase (11%), fatigue (11%), HFSR (6%), and nausea 
(6%) (589).
[Recommendation]
1.  Recurrent HCC after resection, RFA, or liver 
transplantation can be retreated with appropriate 
treatment modalities considering the timing of 
recurrence, residual liver function, performance status, 
and the size, location, and number of recurrent tumors 
(C1).
Refractoriness to Transarterial 
Chemoembolization
cTACE is a standard treatment for patients with 
intermediate-stage HCC based on its survival benefit in 
patients with unresectable HCC reported in previous studies 
(77, 79, 132, 370, 590, 591). Given that TACE is usually 
performed repeatedly in individual HCC patients due to 
its palliative nature (592), development of untreatable 
progression of HCC, in which TACE cannot be considered 
any further, is regarded as TACE refractoriness or failure 
(370, 593-595). Recently, several studies have attempted 
to define TACE refractoriness. In a single-institutional 
study from Korea, researchers defined stage progression 
despite repeated TACEs as a surrogate endpoint of 
TACE refractoriness. They suggested predictors of TACE 
refractoriness as either development of disease progression 
or the need for three sessions of TACE, during the first 6 
months following the initial TACE, which enables prompt 
switching to other treatments (596). However, these criteria 
did not include deterioration of hepatic function, and have 
not been fully validated. The Assessment for Retreatment 
with TACE (ART) score was developed by researchers from 
Austria, which integrated the radiologic tumor response, 
impairment of hepatic function, and liver damage (increase 
in aspartate aminotransferase) (597). The ART score 
identified patients with a poor prognosis (score ≥ 2.5 after 
the first TACE) who would not benefit from repeated TACE 
sessions. Likewise, a French group developed the AFP, BCLC, 
Child-Pugh, and response (ABCR) score which combined 
AFP, tumor stage, change in liver function, and radiologic 
tumor response, suggesting patients with a score ≥ 4 may 
not benefit from further sessions of TACEs (598).
Recent practice guidelines on HCC have defined TACE 
refractoriness in different ways. The guidelines from 
the EASL recommended switching to sorafenib in case 
of untreatable progression on TACE in patients with 
intermediate-stage HCC (77). Previous Korean guidelines 
regarded upward stage migration following repeated TACE as 
refractoriness, suggesting a switch to sorafenib therapy (79). 
Japanese guidelines provided criteria for TACE refractoriness 
as follows: 1) consecutive insufficient tumor response (≥ 
2 sessions); 2) two or more consecutive progressions in 
tumor number; 3) continuous elevation of tumor markers; 
4) development of vascular invasion; and 5) development of 
extrahepatic spread (591).
To date, various definitions of TACE refractoriness exist, 
and a treatment strategy to overcome such a condition has 
not been well established. Sorafenib has been recommended 
as a treatment option for TACE refractoriness based on 
its survival benefit in advanced HCC. A sub-analysis of 
the SHARP trial showed survival benefit of sorafenib in 
patients with prior TACE compared with placebo (599). A 
retrospective study from Japan demonstrated prolonged 
TTP and OS with a switch to sorafenib compared with 
continued TACE in patients with TACE refractoriness 
(600). In a retrospective study including patients with 
TACE refractoriness from Japan, HAIC showed promising 
results in terms of tumor response and survival (601). 
Collectively, direct evidence on the efficacy of various 
treatment modalities in TACE refractoriness is insufficient. 
The therapeutic role of recently developed systemic 
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agents needs to be investigated in the setting of TACE 
refractoriness in the near future.
Given the potential ischemic injury due to tissue ischemia 
following TACE, combination treatment strategies are under 
investigation, such as TACE plus systemic agents with 
antiangiogenic property (e.g., sorafenib) (602). Enrolled 
patients in those clinical trials appear heterogeneous in 
terms of tumor stage (603). In other words, a clinical 
trial designed solely for TACE refractoriness has not yet 
been conducted. Several recent studies on combination 
treatments have reported mixed results. A systematic 
review with a meta-analysis reported that prolonged TTP 
without significant improvement in OS was achieved with 
combined TACE and sorafenib compared with TACE alone 
(604). A global clinical trial of combined sorafenib plus 
TACE with doxorubicin-eluting beads did not reach clinical 
significance in terms of TTP (605). Another large-scale 
European study comparing TACE using drug-eluting beads 
plus sorafenib versus TACE with placebo did not improved 
PFS in unresectable, liver-confined HCC (606). Likewise, an 
Asian multi-institutional study comparing orantinib versus 
placebo combined with TACE did not improve OS in patients 
with unresectable HCC (607). In conclusion, evidence 
supporting combination treatment of TACE and systemic 
agents is insufficient at present.
[Recommendation]
1.  After on-demand two or more session of TACE within 
6 months from the first TACE, development of one 
or more of the following condition in patients with 
unresectable HCC is defined as TACE refractoriness, and 
a switch to other treatments needs to be considered: 
1) absence of objective response (complete or partial 
response); 2) new appearance of vascular invasion; and 
3) new appearance of extrahepatic spread (C1).
Second-Line Therapy after Sorafenib Failure
Sorafenib failure is usually defined as pre-existing 
disease progression or appearance of a new intrahepatic or 
extrahepatic lesion during sorafenib treatment, and various 
patterns of disease progression after sorafenib failure are 
associated with prognosis (608). In clinical practice, the 
median duration of sorafenib administration is 12 weeks 
(523, 609). Long-term administration of sorafenib is often 
prohibited by disease progression, adverse events, and 
deterioration of liver function.
To develop second-line systemic therapy for HCC patients 
who stopped sorafenib due to disease progression or 
adverse events, several phase III clinical trials have been 
conducted using targeted agents such as brivanib, which 
inhibits FGF and VEGF (610), everolimus, which is an mTOR 
inhibitor (611), ramucirumab, which blocks VEGF-2 (612), 
and tivantinib, which is a nonselective c-Met inhibitor (613). 
However, all these new agents failed to show improved 
survival compared with placebo.
Regorafenib
Regorafenib is an oral multikinase inhibitor that blocks 
the activity of protein kinases involved in angiogenesis, 
oncogenesis, metastasis, and tumor immunity. Although 
regorafenib has a similar molecular structure to sorafenib, it 
has a distinct molecular target profile and had more potent 
pharmacological activity than sorafenib in preclinical studies 
(614-616). A international phase III RCT was conducted to 
validate the efficacy and safety of regorafenib as a second-
line therapy for HCC patients with Child-Pugh A function 
and an ECOG score 0–1 who progressed after sorafenib 
treatment. Participants tolerated sorafenib (≥ 400 mg/day 
for ≥ 20 days of last 28 days of treatment), progressed on 
sorafenib, and had Child-Pugh A liver function. They were 
randomly assigned to receive regorafenib or placebo in a 2:1 
ratio fashion. Regorafenib improved OS with an HR of 0.63 
(95% CI, 0.50 to 0.79; p < 0.0001); median survival was 
10.6 months (95% CI, 9.1 to 12.1 months) for regorafenib 
versus 7.8 months (95% CI, 6.3 to 8.8 months) for placebo. 
Based on this result, regorafenib was the first drug to show 
an improvement in survival as second-line systemic therapy 
(617). Median PFS by mRECIST was 3.1 months (95% CI, 
2.8 to 4.2) with regorafenib and 1.5 months (95% CI, 1.4 
to 1.6 months) with placebo (p < 0.001). Median TTP by 
mRECIST was 3.2 months (95% CI, 2.9 to 4.2 months) with 
regorafenib and 1.5 months (95% CI, 1.4 to 1.6 months) 
with placebo (p < 0.001). The mean duration of regorafenib 
administration was 5.9 months and that with sorafenib was 
3.3 months. Grade 3 or 4 adverse events associated with 
regorafenib were hypertension (15%), HFSR (13%), fatigue 
(9%), and diarrhea (3%) (617).
Nivolumab
Nivolumab, a checkpoint inhibitor, is a fully human 
IgG4- type, monoclonal inhibitory antibody against PD-
1. As an anti-PD-1 inhibitor, it binds to the PD-1 receptor 
on the T-cell to restore the suppressed tumor-killing 
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effect. In a phase I/II, open-label, non-comparative, dose 
escalation and expansion trial of nivolumab, patients with 
histologically confirmed HCC with or without hepatitis C or 
B infection were recruited. The patients had compensated 
liver function (Child-Pugh score ≤ 6 in the dose expansion 
group, ≤ 7 in the dose escalation group), ECOG score 0–1, 
and HBV DNA < 100 IU/mL if the etiology was HBV (529).
Patients received intravenous nivolumab 0.1 to 10 mg/kg 
every 2 weeks in the dose-escalation phase and nivolumab 
3 mg/kg was administered every 2 weeks in the dose-
expansion phase in four cohorts: sorafenib untreated 
or intolerant patients without viral hepatitis, sorafenib 
progression patients without viral hepatitis, HCV infected 
patients, and HBV infected patients. The primary endpoints 
were safety and tolerability for the escalation phase and 
OSS for the expansion phase. In a total of 262 treated 
patients (48 in the dose-escalation phase and 214 in the 
dose-expansion phase), the response rate was 20% (95% 
CI, 15% to 26%) in the dose-expansion phase and 15% 
(95% CI, 6% to 28%) in the dose-escalation phase. Three 
patients (6%) had treatment-related SAEs (pemphigoid, 
adrenal insufficiency, and liver disorder) (529, 530). The 
U.S. Food and Drug Administration conditionally approved 
nivolumab as a second-line therapy after sorafenib failure 
based on the results of a randomized phase I/II trial, and 
it is also prescribed in Korea. However, the final approval 
of nivolumab as first-line therapy for HCC needs data from 
CheckMate-459 (ClinicalTrials.gov ID: NCT02576509), which 
is a phase III, multi-institutional, RCT to compare the 
efficacy and safety of nivolumab.
Cabozantinib
Cabozantinib is an oral, molecular targeted agent which 
blocks MET, VEGFR-2, and RET. An international phase III 
RCT was conducted to validate the efficacy and safety of 
cabozantinib as second- or third-line therapy in patients 
with advanced HCC who failed sorafenib treatment and had 
Child-Pugh A liver function and ECOG score 0–1. Enrolled 
patients had showed progressive diseases in spite of one 
or two systemic therapies, including sorafenib, prior to 
participating in the study. The primary endpoint was OS, 
and the secondary endpoint was PFS and ORR according 
to RECIST 1.1. Among all the participants, 27% received 
two systemic therapies, including sorafenib. The median 
OS in the cabozantinib group was 10.2 months, which was 
significantly longer than 8.0 months in control group (HR, 
0.76; 95% CI, 0.63 to 0.92; p = 0.0049). Thus, the clinical 
trial met the primary endpoint. In subgroup analysis, among 
patients who experienced sorafenib alone, the median OS 
in the cabozantinib group was 11.3 months, which was also 
significantly longer than 7.2 months in the control group 
(stratified HR, 0.70; 95% CI, 0.55 to 0.88). The median 
PFS was longer in the cabozantinib group (5.2 months) 
than in the control group (1.9 months) (HR, 0.44; 95% CI, 
0.36 to 0.52; p < 0.001), and ORR was also higher in the 
cabozantinib group than in the control group (4% vs. 0.4%, 
p = 0.0086). The median duration of cabozantinib therapy 
was 3.8 months. The grade 3 or 4 adverse events were 
reported in 68% of the patients in the cabozantinib group 
and in 36% in the placebo group. The most common grade 
3 or 4 AEs were HFSR (17%), hypertension (16%), elevation 
of transaminase levels (12%), fatigue (10%), and diarrhea 
(10%) (618).
Ramucirumab
Ramucirumab is an intravenous monoclonal antibody 
targeting VEGFR-2. A phase III RCT (REACH, ClinicalTrials.
gov ID: NCT01140347) of ramucirumab as a second-line 
therapy for patients with advanced HCC who failed sorafenib 
was conducted. The trial failed to meet the primary 
endpoint of improvement of OS compared with control 
(612). However, in a post-hoc subgroup analysis, the OS 
in patients with a serum AFP level ≥ 400 ng/mL was 7.8 
months, which was significantly higher than 4.2 months in 
the placebo group (HR, 0.67; 95% CI, 0.51 to 0.90). Based 
on this result, a subsequent phase III RCT of 2:1 assignment 
to ramucirumab or placebo for patients with high AFP 
levels (REACH-2, ClinicalTrials.gov ID: NCT02435433) was 
conducted. Enrolled patients had progressive HCC even 
after sorafenib or stopped sorafenib due to adverse events. 
The Child-Pugh class in the patients was A, the ECOG score 
was 0 to 1, and the serum AFP level was ≥ 400 ng/mL. The 
primary endpoint of the study was OS. The OS in patients 
who received 8 mg/kg of ramucirumab every 2 weeks was 
8.5 months, which was significantly longer than 7.3 months 
in the placebo group (HR, 0.71; 95% CI, 0.531 to 0.949; 
p = 0.0199). Thus, the trial met the primary endpoint. The 
median PFS in the ramucirumab group was 2.8 months, 
which was also significantly longer than 1.6 months in the 
control group (HR, 0.452; 95% CI, 0.339 to 0.603; p < 
0.0001). The DCR in the ramucirumab and control group 
was 59.9% and 38.9%, respectively (p = 0.0006); however, 
there was no difference in ORR between the two groups. 
The median duration of ramucirumab administration was 
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12 weeks. SAE of any grade and cause were recorded in 
35% of participants in the ramucirumab group and 29% in 
the placebo group. The most common grade 3 or 4 adverse 
event that were noted in 5% or more of patients was 
hypertension and hyponatremia (619).
Cytotoxic Chemotherapy and Hepatic Arterial Infusion 
Chemotherapy
Cytotoxic chemotherapy can be considered for patients 
with HCC for whom primary or secondary systemic 
treatments—such as sorafenib, lenvatinib, regorafenib, 
nivolumab, cabozantinib, and ramucirumab— have failed, 
or for patients with progressive HCC for whom systemic 
treatments cannot be used, but who have good remnant 
liver function (620-622).
Doxorubicin is the most commonly used systemic drug for 
HCC treatment; however, in most cases, the response rate 
of patients taking doxorubicin is less than 20% (623-625). 
Other systemic treatments, including 5-fluorouracil (626), 
gemcitabine (627, 628), oxaliplatin (629), capecitabine 
(630), irinotecan (631), octreotide (632, 633), interferon 
(634), and tamoxifen (635), also failed in demonstrating 
effectiveness and improving survival rates. Combination 
chemotherapy has been tested, since single-drug therapy 
had minimal effects on HCC. FOLFOX (oxaliplatin/
fluorouracil/leucovorin) combination therapy has been 
studied the most. A multicenter RCT (EACH study) including 
317 Asian patients (China [70%], Korea [14%], Thailand 
[11%], and Taiwan [5%]) compared FOLFOX combination 
chemotherapy with doxorubicin single-drug therapy. The 
combination chemotherapy did not significantly extend 
median survival time, which was the primary outcome 
measure (6.4 months vs. 2.9 months; p = 0.07) or the PFS 
time (2.9 months vs. 1.77 months; p < 0.01). Moreover, 
the stable disease rate (52.2% vs. 31.6%; p < 0.001) was 
higher compared with doxorubicin single-drug therapy 
(636). Interestingly, sub-analysis of the results of Chinese 
patients alone in the EACH study suggested that FOLFOX 
combination chemotherapy significantly extended survival 
time compared with doxorubicin single-drug therapy (637).
A multicenter retrospective study of 204 patients with 
progressive HCC evaluated the effectiveness of GEMOX 
(oxaliplatin/ gemcitabine) combination therapy. The PFS 
time and OS time were 4.5 months and 11.0 months, 
respectively (638). Another retrospective study of 40 
patients with progressive HCC not responding to sorafenib 
therapy also evaluated the effectiveness of GEMOX 
combination chemotherapy as a secondary anticancer 
therapy. The partial response and stable disease rates in 
this study were 20% and 46%, respectively. The PFS time 
was 3.1 months and the median survival time was 8.3 
months (639).
A meta-analysis of 17 oxaliplatin clinical studies 
comprising 800 patients revealed that the partial reaction 
rate was 16%, while the median PFS and median OS were 4.2 
months and 9.3 months, respectively (640). Another meta-
analysis, which included studies written in Chinese (641), 
suggested that the partial reaction rate of combination 
chemotherapy, including oxaliplatin, was 14%, while the 
median PFS time and median OS time were 4.7 months and 
9.5 months, respectively.
In most cases, HCC is accompanied by cirrhosis, which 
affects the absorption and metabolism of anticancer drugs. 
Therefore, drug-induced toxicity may increase, and often 
administration of the therapeutic dose becomes impossible 
(642). Therefore, cytotoxic chemotherapy needs to be used 
in a limited manner in HCC patients with good systemic 
condition and liver function. To prevent a decline in the 
quality of life, less toxic drugs need to be used as per the 
requirements for each case or dose reduction needs to be 
considered if the drug has strong toxicity.
HAIC is a type of cytotoxic chemotherapy that involves 
direct injection of the cytotoxic anticancer drugs into 
the hepatic artery, thus causing fewer adverse systemic 
reactions, while exposing HCC to high concentrations of 
anticancer drugs. The most commonly used HAIC drug is 
5-fluorouracil, which is used alone or in combination with 
cisplatin. Studies have shown that the overall response rate 
in patients with progressive HCC was 3.8% to 38.5% with 
a partial response rate of 7% to 81% and a median survival 
time of 5 to 19.5 months (643-647). A long term (median 
follow-up period: 28 years) retrospective study conducted 
in Japan evaluated the outcomes of HAIC treatment in 
14246 cases. The 5-year survival rate was 32% and the 
median survival time was 31 months. Moreover, the results 
were similar to that of cTACE (647). Factors affecting the 
poor outcomes of HAIC treatment were the remaining liver 
function and an increased Child-Pugh score assessed 4 
weeks after HAIC treatment (648). There are no reports 
of a prospective study that directly compared the efficacy 
of sorafenib with that of HAIC. However, a retrospective 
study suggested that HAIC resulted in a longer survival 
time and higher tumor response than sorafenib (648-651), 
but there was no difference in survival time between the 
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two groups. A sub-analysis of progressive HCC patients 
with hepatic portal vein invasion also suggested that 
HAIC produced better results than sorafenib (652). A 
domestic multicenter retrospective study of progressive HCC 
patients with main hepatic portal vein invasion compared 
HAIC and TACE. This study showed that HAIC resulted in 
higher tumor response and survival rates than TACE (118). 
A phase II RCT conducted in Japan in a small group of 
patients with progressive HCC revealed that the sorafenib-
HAIC combination chemotherapy group had higher survival 
rates than the sorafenib single-drug therapy group (653). 
In contrast, a phase III RCT in 210 patients showed 
no difference in survival rates between the sorafenib-
HAIC combination chemotherapy group and the sorafenib 
monotherapy group (654).
[Recommendations]
1.  Regorafenib is recommended for patients with 
progressive HCC after at least 3 weeks of sorafenib (≥ 
400 mg/day) treatment and with Child-Pugh class A 
and good performance status (ECOG score 0–1) (A1).
2.  Nivolumab could be used for patients with progressive 
HCC after sorafenib or for those intolerant of sorafenib 
and with Child-Pugh class A and good performance 
status (ECOG score 0–1) (B2).
3.  Cabozantinib is recommended for patients with 
progressive HCC after one or two systemic therapies 
including sorafenib and with Child-Pugh class A and 
good performance status (ECOG score 0–1) (A1).
4.  Ramucirumab has shown survival benefit in patients 
with progressive HCC and serum AFP level ≥ 400 ng/mL 
after sorafenib treatment or sorafenib-intolerance and 
with Child-Pugh class A, ECOG score 0–1 (A2).
5.  Cytotoxic chemotherapy can be considered for patients 
with HCC for whom primary or secondary systemic 
treatments, such as sorafenib, lenvatinib, regorafenib, 
nivolumab, cabozantinib, or ramucirumab have failed, 
or cannot be used, and who still have both good liver 
function and good performance status (C1).
6.  HAIC might be considered for patients with progressive 
HCC and portal vein invasion for whom systemic 
therapies, such as sorafenib, lenvatinib, regorafenib, 
nivolumab, cabozantinib, or ramucirumab, have failed 
or cannot be used, and who still have both good liver 
function and good performance status (C2).
Preemptive Antiviral Treatment
HBV-Related HCC
The rate of HBV reactivation in HCC patients after 
cytotoxic chemotherapy varies widely from 30% to 60% 
(655, 656), and the subsequent mortality rate is reported 
to be approximately 30% of all deaths resulting from 
HBV reactivation. HBV reactivation with concomitant 
elevation of the serum HBV DNA level or abnormality of 
biochemical liver function is observed in 20% to 50% of all 
HBV carriers who receive immunosuppressants or cytotoxic 
chemotherapy for the treatment of malignancies other than 
HCC (e.g., breast cancer, hematologic malignancies, and 
other solid cancers) (655, 657-660). Therefore, the test for 
HBsAg must be performed in patients at high risk of HBV 
infection prior to immunosuppressive therapy or cytotoxic 
chemotherapy (661). Antiviral drugs should be preemptively 
administered in HBV carriers at the onset of the cytotoxic 
chemotherapy or immunosuppressant administration and 
must be continued for at least 6 months. Although further 
research is required to clarify the adequate serum HBV DNA 
level, recurrence is more likely after the discontinuation of 
antiviral drugs in patients with high HBV DNA levels prior 
to cytotoxic chemotherapy. Therefore, in patients with HBV 
DNA levels > 2000 IU/mL prior to cytotoxic chemotherapy, 
continuation of antiviral treatment should be considered 
until the treatment goal of chronic hepatitis B is reached 
(661). Most studies on preemptive antiviral treatment are 
limited to lamivudine; however, other recently developed 
antiviral drugs can be used. In cases of lamivudine 
resistance, antiviral drugs should be replaced according 
to the treatment guidelines for resistance (662, 663). In 
particular, in cases in which antiviral therapy is expected 
to continue for more than 12 months, the antiviral drug 
with the minimum resistance profile should be selected 
(664). Interferon is not recommended as a preemptive 
treatment because of the risk of bone marrow suppression 
and transient aggravation of hepatitis. In HBsAg-negative, 
anti-HBc-positive, and anti-HBs-positive patients, HBV 
reactivation can develop very rarely, and there is little 
evidence to recommend uniform preemptive treatment 
owing to a lack of research (661).
Many studies have evaluated HBV reactivation during 
TACE for the treatment of HCC; HBV reactivation is reported 
to occur in 4% to 40% of patients (655, 656, 665-668). 
According to a study comparing preemptive lamivudine 
treatment to an untreated control group during TACE 
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(666), significant differences were observed with respect 
to HBV reactivation (2.8% and 40.5%), as well as the 
consequent occurrence of hepatitis (2.8% and 19.7%) and 
liver failure (0% and 8.1%). Another study (669) compared 
preemptive entecavir treatment and an untreated control 
group following TACE treatment and reported a significant 
difference in virus-related events (6.8% and 54.4%) and 
acute decompensation (0% and 11.6%) (670). Hence, 
preemptive antiviral treatment can be considered for HBV-
positive HCC patients undergoing TACE. However, differences 
in chemotherapeutic agents, and treatment interval and 
frequency may have resulted in discordant HBV reactivation 
rates (666-668). Therefore, additional research is required 
to determine the serum HBV DNA levels and biochemical 
liver function test levels that require preemptive antiviral 
treatment.
HBV reactivation rates after HAIC for HCC (24% to 67%) 
are reported to be higher than those after TACE, which is 
possibly because of the higher dose of chemotherapeutic 
agents, as HAIC is carried out in shorter intervals (656, 
671, 672). However, more research is needed to support the 
claim that HAIC has a higher reactivation rate than TACE, 
as only a few studies with a limited number of participants 
have been reported and no comparative study with TACE has 
been performed.
Following surgical resection of HCC, HBV reactivation with 
concomitant elevation in the HBV DNA level or an abnormal 
biochemical liver function test is observed in 14% to 32% of 
patients (673). In a prospective study comparing preemptive 
telbivudine administration to an untreated control group 
from the day of resection, the HBV reactivation rates were 
2.5% and 31.8%, respectively. While 57.1% of the control 
group showed HBV reactivation within 1 week following 
surgical resection, only 2.5% of the telbivudine-administered 
group showed reactivation within 4 weeks. The authors of 
that study recommend preemptive antiviral treatment before 
the surgical resection of HCC (664).
In an RCT comparing preemptive adefovir therapy to a 
control group after R0 resection, the 1-, 3-, and 5-year RFS 
rates were superior in the adefovir group compared with the 
control group (85.0%, 50.3%, and 46.1% vs. 84.0%, 37.9%, 
and 27.1%, respectively) (674). The corresponding OS rates 
were also superior in the adefovir group (96.0%, 77.6%, 
and 63.1% vs. 94.0%, 67.4%, and 41.5%, respectively). The 
relative risks of recurrence and death for antiviral treatment 
were 0.651 and 0.420, respectively. Antiviral therapy was an 
independent protective factor for late tumor recurrence (673).
A study comparing preemptive lamivudine administration 
and an untreated control group following radiotherapy for 
HCC reports the HBV reactivation rates to be 0% and 21.8%, 
respectively; meanwhile, alanine transaminase elevation 
occurred in 2.3% and 12.5% of patients, respectively (675). 
Another recent report suggests concurrent TACE and 
external radiotherapy may double the HBV reactivation rate 
compared with TACE alone (670). However, it is difficult to 
recommend preemptive antiviral treatment before external 
radiotherapy for HCC because of the lack of controlled 
prospective studies.
There are limited studies regarding HBV reactivation from 
PEI or RFA; nonetheless, the HBV reactivation rates for 
these therapies are reported to be 0% and 5.6% to 9.1%, 
respectively (676, 677).
HBV reactivation during sorafenib treatment is currently 
controversial. A Korean retrospective study reported no 
HBV reactivation during sorafenib treatment (523). While 
another study reported a higher risk of HBV reactivation 
during sorafenib treatment (678).
In hepatitis B patients with a high viral load, antigen-
specific T cells are functionally exhausted, which is caused 
by immune checkpoints such as PD-1 (679). In HBV e 
antigen (HBeAg)-positive chronic hepatitis B patients 
with a high viral load, the number of PD-1 and cytotoxic 
T-lymphocyte antigen 4 (CTLA-4)-positive T cells increased. 
Therefore, blockade of PD-1 using immune checkpoint 
inhibitors could lead to activation of CD8+ T-effector cells, 
leading to increased HBV core antigen (HBcAg)-specific 
interferon gamma expression. Therefore, in patients with a 
high HBV viral load, HCC treatment with immune checkpoint 
inhibitors could cause liver injury through T cell activation. 
In conclusion, in HBV-related HCC patients receiving 
immune checkpoint inhibitor treatment, such as nivolumab, 
effective antiviral treatment should be considered to lower 
HBV DNA levels.
HCV-Related HCC
Regarding HCV-related HCC, there are almost no reported 
cases of HCV reactivation or aggravation of hepatitis after 
HCC treatment. In a recent retrospective study on hepatitis 
virus reactivation comparing HCV- and HBV-related HCC 
after TACE, the rates of viral reactivation, hepatitis, and 
liver failure were 26.5%, 10.2%, and 0%, respectively, in 
HCV-related HCC patients and 32.5%, 34.8%, and 10.9%, 
respectively, in HBV-related HCC patients (680). No 
significant difference was observed between the HCV and 
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HBV groups with respect to the reactivation rate, but the 
risk of hepatitis and liver failure were significantly lower 
in the HCV-related HCC group. Hepatitis C treatments can 
be considered in patients with active chronic hepatitis C 
and completely eradicated HCC. As interferon and ribavirin 
administration may cause bone marrow suppression 
and transient aggravation of hepatitis, they are not 
recommended as preemptive treatments before cytotoxic 
chemotherapy in HCC patients.
[Recommendations]
1.  Patients should be tested for hepatitis B surface 
antigen before starting cytotoxic chemotherapy or 
immunosuppressive therapy (A1).
2.  Preemptive antiviral therapy is recommended for HBV 
carriers undergoing cytotoxic chemotherapy to prevent 
reactivation (A1). Preemptive antiviral therapy is 
considered for HBV-infected patients receiving TACE 
(B1), HAIC (C1), surgical resection (C1), EBRT 
(C1), or immune checkpoint inhibitor therapy (C1) 
to prevent reactivation. Preemptive antiviral therapy 
with DAAs cannot be recommended for HCV carriers 
undergoing HCC treatments.
Drug Treatment for Cancer Pain in HCC
The prevalence of pain in cancer patients ranges from 
45% to 53% (681-683). Early, aggressive palliative care 
including pain management could improve quality of life 
in cancer patients (684-686) and could improve survival in 
lung cancer patients (687). A few studies have investigated 
the prevalence of pain in HCC patients, which is reported 
to range from 22% to 66.8% (682, 688, 689). Therefore, 
pain management should be considered an important aspect 
of palliative care for HCC patients. As most HCC patients 
have chronic liver disease and/or liver cirrhosis, their drug 
metabolism may be altered according to the degree of liver 
dysfunction (690). Furthermore, HCC patients receiving 
analgesics may suffer from more frequent and severe side 
effects. However, there is a paucity of studies on pain 
management for patients with HCC and liver disease (691). 
Therefore, drug treatment for cancer pain in HCC patients 
should generally follow the principles of pain management 
for general solid tumors (692-694). However, drug 
selection, dosage, and administration interval might need 
to be adjusted according to the degree of liver function 
impairment. 
The universal strategy for cancer pain treatment is based 
on a sequential three-step analgesics ladder approach 
from non-opioids to weak opioids and finally to strong 
opioids according to pain intensity and the efficacy of pain 
control (692-694). The main non-opioid analgesics, such as 
acetaminophen and nonsteroidal anti-inflammatory drugs 
(NSAIDs), are indicated for the treatment of mild pain 
(numerical rating scale, 1 to 3). Meanwhile, weak opioids, 
such as codeine, hydrocodone, and tramadol, are indicated 
for mild to moderate pain (numerical rating scale, 4 to 
6). Finally, strong opioids, such as morphine, oxycodone, 
hydromorphone, fentanyl, and their analogues are the 
mainstay of analgesics for treating moderate to severe 
cancer-related pain (numerical rating scale, 7 to 10). 
Acetaminophen is the most common cause of fulminant 
hepatic failure (44, 58, 695, 696), however, clinically 
significant hepatic injury is very rare when the dosage 
is limited to 4 g/day (697). Nonetheless, it has been 
recommended that the dosage of acetaminophen per unit 
(tablet or capsule) in all prescription analgesics combined 
with acetaminophen should be limited to less than 325 
mg of acetaminophen to avoid liver injury (698). Although 
one case report demonstrates that even therapeutic doses 
of acetaminophen less than 4 g/day in alcoholic patients 
without liver cirrhosis can result in acute liver failure (699), 
other studies show that 4 g/day in alcoholic patients is 
not associated with a significant increase in liver toxicity 
(700, 701) Moreover, one study shows a significant increase 
in the liver enzyme levels of alcoholic patients taking 
acetaminophen 4 g/day (702). In patients with cirrhosis, 
acetaminophen 2–3 g/day is not associated with acute 
hepatic decompensation (703). Even though the half-life 
of oral acetaminophen is twice as long in patients with 
cirrhosis compared with that in healthy controls (704), 
significant hepatic injury is rare in patients with liver 
disease and/or cirrhosis at a dosage of less than 4 g/day 
(704, 705). Nonetheless, most experts recommend lowering 
the dosage of acetaminophen to 2–3 g/day in patients with 
liver cirrhosis because of the possibility of altered drug 
metabolism and increased half-life (706, 707).
The unbound drug concentrations of NSAIDs are generally 
elevated in liver disease patients, which can lead to more 
severe side effects and toxicity (708). Indeed, roughly 
10% of total drug-induced hepatotoxicity cases are related 
to NSAIDs (709), and NSAID-induced liver injury is well 
documented (695, 710). Moreover, NSAIDs can cause 
adverse effects, including nephrotoxicity (711), gastric 
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ulcer, hemorrhage (59, 60, 712, 713), and decompensation 
of liver function (703).
As the liver is the major site of metabolism for most 
opioids, impaired metabolism and excretion of opioids 
due to underlying liver disease in HCC patients can lead 
to increased side effects. Moreover, opioids are well-
known major precipitants of hepatic encephalopathy (705). 
Therefore, careful selection of the correct opioid, and dosage 
and interval adjustment of drugs are required according to 
the liver metabolism of each opioid (707, 714). Morphine is 
an active analgesic compound by itself, and more than 90% 
of metabolites are renally excreted after glucuronidation in 
the liver. The half-life of morphine is approximately twice 
as long in cirrhosis patients as that in healthy controls 
(715, 716). Furthermore, its bioavailability is 4-fold greater 
in patients with HCC (68%) than in healthy controls (17%) 
(717). As the analgesic effect of codeine is presumed to 
be secondary following its conversion to morphine, it is 
not expected to be present in serum. The ceiling effect of 
codeine may cause side effects before achieving a sufficient 
analgesic effect. Similarly, hydrocodone is metabolized to 
hydromorphone before producing an analgesic effect, which 
results in variable serum levels. Meanwhile, tramadol has a 
10-fold lower affinity for opioid receptors than codeine and 
exerts its analgesic effect via the peripheral pain pathway, 
which may result in fewer side effects in patients with 
liver disease. However, its elimination half-life is up to 
3-fold greater in patients with primary liver carcinoma than 
that in controls (718). Oxycodone is converted to various 
metabolites including oxymorphone (an active metabolite), 
which may result in variable serum levels of metabolites and 
an unpredictable analgesic effect. The elimination half-life 
of oxycodone is prolonged, while its clearance is diminished 
with significant ventilation depression in pre-liver 
transplantation liver cirrhosis patients compared with post-
liver transplantation patients (719). Hydromorphone is an 
active analgesic compound by itself and is metabolized and 
excreted after glucuronidation. Liver dysfunction does not 
have a particularly substantial effect on hydromorphone; 
the half-life of hydromorphone does not differ significantly 
in patients with moderate hepatic impairment compared 
with controls (720). Although fentanyl is metabolized by 
cytochrome, its metabolism does not yield toxic metabolites 
or significantly alter serum levels in cirrhosis patients. 
Furthermore, it is not influenced by renal dysfunction (707, 
714, 721).
[Recommendations]
1.  Careful consideration is required for pain management 
with medication in patients with HCC and underlying 
liver disease. The dosage and dosing intervals of 
analgesics should be determined on the basis of liver 
function (C1).
2.  In patients with HCC and chronic liver disease, the 
dosage of acetaminophen should be lowered (C1) and 
NSAIDs should be used with caution (B1).
3.  In patients with HCC and chronic liver disease, opioid 
analgesics and their dosage should be selected 
carefully on the basis of drug metabolism and liver 
function (C1).
Assessment of Tumor Response and Post-
Treatment Follow-Up
Tumor Response
The major primary aim of cancer treatment research is the 
improvement of OS. Nonetheless, tumor response and TTP 
are also considered pivotal for the surrogate assessment 
of efficacy. In oncology, tumor response was initially 
measured according to the 1979 WHO criteria (Table 7) 
(722). However, several problems arose when applying 
these definitions to clinical practice. For example, there 
were discrepancies in the criteria for measuring tumor size 
among researchers. Furthermore, some researchers define 
progressive disease on the basis of the change in the size 
of one tumor, while others define it on the basis of the sum 
of the changes in the sizes of all tumors. Another limitation 
of the WHO criteria is properly reflecting the changes in 
tumor volume determined by recent advanced CT and MRI 
technologies. In order to overcome these problems, the 
RECIST criteria and RECIST version 1.1 were developed 
and released in 2000 and 2009, respectively (723, 724). 
However, these criteria were primarily designed to evaluate 
cytotoxic agents. Therefore, they do not address measures 
of antitumor activity besides tumor shrinkage; thus, the 
best response in these criteria might be stable disease. 
As acknowledged in the original RECIST publication, 
assessments based solely on changes in tumor size can 
be misleading when applied to other anticancer drugs, 
such as molecular targeted therapies or other therapeutic 
interventions (725). Therefore, these determinations may 
be inaccurate. Several clinical studies on HCC demonstrate 
that the RECIST criteria do not mirror the extent of tumor 
necrosis induced by interventional therapies or new 
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molecular targeted drug (514, 726). In theory, viable tumor 
formation should be assessed by CT or MRI studies, and 
tumor viability should be defined according to the uptake 
of contrast agent in the arterial phase of dynamic imaging 
studies. In fact, extensive tumor necrosis, which develops 
after local treatment, may not be paralleled by a decrease 
in lesion diameter. To overcome these limitations, the EASL 
developed new criteria for HCC treatment response that take 
Table 7. Assessment of Tumor Response*
RECIST mRECIST
Target lesions response
CR
Disappearance of all target lesions Disappearance of any intratumoral arterial enhancement  
  in all target lesions
PR 
At least 30% decrease in sum of diameters of 
  target lesions, taking as reference baseline
  sum of diameters of target lesions
At least 30% decrease in sum of diameters of  
   viable (enhancement in arterial phase) target lesions, 
taking as reference baseline sum of diameters of target 
lesions
SD Any cases that do not qualify for either PR or PD Any cases that do not qualify for either PR or PD
PD
Increase of at least 20% in sum of  
   diameters of target lesions, taking as reference 
smallest sum of diameters of target lesions 
recorded since treatment started
Increase of at least 20% in sum of diameters  
   of viable (enhancing) target lesions, taking as 
reference smallest sum of diameters of viable 
(enhancing) target lesions recorded since treatment 
started
Non-target lesions response
CR
Disappearance of all nontarget lesions Disappearance of any intratumoral arterial enhancement  
  in all nontarget lesions
IR/SD
Persistence of one or more nontarget lesions Persistence of intratumoral arterial enhancement in one  
  or more nontarget lesions
PD
Appearance of one or more new lesions and/or  
   unequivocal progression of existing nontarget 
lesions
Appearance of one or more new lesions and/or  
  unequivocal progression of existing nontarget lesions
mRECIST recommendations
Pleural effusion
  and ascites
Cytopathologic confirmation of neoplastic nature of any effusion that appears or worsens during  
  treatment is required to declare PD
Porta hepatis lymph node
Lymph nodes detected at porta hepatis can be considered malignant if lymph node short axis is at  
  least 2 cm
Portal vein invasion
Malignant portal vein invasion should be considered as non-measurable lesion and thus included in  
  nontarget lesion group
New Lesion
New lesion can be classified as HCC if its longest diameter is at least 1 cm and enhancement pattern  
   is typical for HCC. Lesion with atypical radiological pattern can be diagnosed as HCC by evidence of at 
least 1 cm interval growth
Overall Response Assessment in mRECIST
Target Lesions Nontarget Lesions New Lesions Overall Response
CR CR No CR
CR IR/SD No PR
PR Non-PD No PR
SD Non-PD No SD
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
*Adapted from European Association for the Study of the Liver, et al. J Hepatol 2012;56:908-943 (77) and Lencioni et al. Semin Liver 
Dis 2010;30:52-60 (728), with permission of Georg Thieme Verlag KG. CR = complete response, IR = incomplete response, mRECIST = 
modified RECIST, PD = progressive disease, PR = partial response, RECIST = Response Evaluation Criteria in Solid Tumors, SD = stable 
disease
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into account the degree of necrosis (727). Furthermore, 
mRECIST criteria were first proposed by a panel of experts 
(551, 728). This proposal is based on the fact that the 
diameter of the target lesions with viable tumors should 
guide all assessments. Specific modifications to the original 
criteria regarding the assessment of vascular invasion, 
lymph nodes, ascites, pleural effusion, and new lesions are 
summarized in Table 7. However, a limitation that should be 
noted is that the assessment of the response to treatment 
based on the mRECIST criteria can be influenced by the 
image quality of CT/MRI, as well as the subjective decisions 
of radiologists.
Pseudo-progression can be observed in the early phase 
of treatment in patients who are receiving immune therapy. 
An incorrect diagnosis of progressive disease could be 
made if the RECIST criteria were considered for assessment 
of tumor response to these agents. Thus, the modified 
RECIST 1.1 for immune-based therapeutics (termed iRECIST) 
was suggested for the assessment of tumor response 
after immune therapy. The iRECIST is characterized by 
unconfirmed progressive disease (iUPD) and confirmed 
progressive disease (iCPD). Unconfirmed progressive disease 
was judged by initial observation of progressive disease, 
which becomes confirmed progressive disease when the 
tumor size gradually increases or new lesions are observed 
in subsequent imaging studies. Further validation and 
improvement should be undertaken for the assessment of 
future developing immune therapies (729).
Although these criteria were validated for the prediction 
of treatment outcome and prediction prognosis in several 
retrospective studies, future studies should be followed for 
efficacy in a large prospective cohort. Because there is no 
solid evidence indicating which set of criteria is superior, 
the panel of experts recommends determining whether a 
set of criteria outperforms the conventional RECIST criteria, 
as well as identifying correlations with pathologic studies 
and outcome prediction. Tumor markers are useful when 
recurrence is suspected without obvious radiologic evidence 
or when measurement of tumor size is difficult. However, 
the assessment of treatment response should not be made 
only using tumor marker (730).
[Recommendation]
1.  Assessment of response should follow both the RECIST 
and mRECIST criteria using dynamic contrast enhanced 
CT or MRI (B1).
Follow-Up after Complete Response
Follow-up data after a complete response in HCC are 
very limited. In cases of a complete response after hepatic 
resection, transplantation, or percutaneous local ablation, 
follow-up studies should be made by dynamic contrast-
enhanced CT or MRI along with assessment of liver function, 
and follow-up intervals are determined on the basis of 
pretreatment risk factors and the treatment-specific risk of 
recurrence.
Recurrence usually develops within 2 years after 
potentially curative treatments. Because early detection 
of recurrence allows the possibility of the reapplication of 
curative treatment modalities, posttreatment monitoring 
should be performed frequently enough to detect recurrence 
as early as possible (731). However, the ideal monitoring 
intervals and methods require further research. Therefore, 
we recommend follow-up with dynamic enhanced imaging 
(i.e., CT or MRI) or MRI with liver-specific contrast agent 
every 2 to 6 months for the first 2 years after curative 
treatment. After 2 years without recurrence, follow-up 
can be performed at 6-month intervals (71, 77, 732). In 
addition, the monitoring interval should be individualized 
on the basis of patient-specific risk factors according to 
tumor biology and underlying liver diseases (733-735).
[Recommendation]
1.  Patients with a complete response after treatment 
should be followed up with imaging studies (i.e., 
dynamic contrast-enhanced CT/MRI or MRI with liver-
specific contrast agents) and serum tumor markers 
every 2 to 6 months in the first 2 years; thereafter, 
patients should be followed by regular checkups at 
individualized intervals (B1).
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Supplementary Table 3. List of Clinical Questions
Internal Medicine
1. Could incidence of HCC be reduced by primary, secondary, or tertiary prevention?
P:  General public subject to preventive measures (primary prevention), group with risk of HCC (secondary prevention), and group 
with risk of HCC recurrence (tertiary prevention)
I: Group that underwent preventive measures
C: Group that did not undergo preventive measures
O: HCC incidence rate (primary and secondary prevention), recurrence rate (tertiary prevention), survival rate
1-1. Does DAA reduce HCC incidence in chronic hepatitis C?
P: Group of patients with chronic hepatitis C
I: DAA treatment group
C: Non-DAA treatment group
O: HCC incidence rate
2. Can HCC surveillance test reduce mortality in high-risk group?
P: Group with high risk of liver cancer
I: Group that underwent liver cancer surveillance test
C: Group that did not undergo liver cancer surveillance test
O: Mortality related to HCC
3. What should be done for indeterminate nodule not definitively diagnosed by imaging?
P: Patients with indeterminate nodules that cannot be diagnosed definitively as HCC
I: Pathologic diagnosis through biopsy
C: Repeated imaging and follow-up of tumor markers
O: Accuracy of diagnosis
4. What tests should be performed to investigate extrahepatic spread after HCC diagnosis?
P: Patients diagnosed with HCC
I: Additional imaging performed
C: Additional imaging not performed
O: Evaluation of extrahepatic spread and accurate staging
5. What HCC staging system is suitable for Korea?
P: HCC staging system
I: mUICC staging
C: Non-mUICC staging
O: Accuracy in prediction of prognosis and treatment plan
6. What criteria can we use to assess response to HCC treatment?
P: HCC patients
I: Assessment of tumor response (WHO criteria, RECIST, mRECIST, RECIST 1.1, iRECIST, Choi criteria)
C: Survival rate
O: Correlation
7.  At what intervals and how should we follow up recurrence after radical treatment, such as locoregional therapies, hepatic resection, 
liver transplantation, etc.?
P: HCC patients with radical treatment
I: Dynamic contrast-enhanced imaging
C: Alternate interval (3 months/6 months/9 months/12 months) test
O: HCC incidence rate, survival rate
8. Is additional anticancer adjuvant therapy or immunotherapy necessary after radical hepatic resection or locoregional therapy?
P: Patients who underwent radical hepatic resection or locoregional therapy
I: Additional adjuvant therapy, such as anticancer treatment or immunotherapy
C: Monitoring without additional adjuvant therapy
O: Decrease in recurrence rate, increase in survival rate
Supplementary Table 3. List of Clinical Questions (Continued)
9. After full recovery of HCC, does DAA increase recurrence of HCC?
P: Group showing full recovery after HCC treatment
I: DAA treatment group
C: Non-DAA treatment group
O: HCC recurrence rate
10.  What is suitable secondary treatment for HCC that has recurred after radical treatment, such as locoregional therapies, hepatic 
resection, liver transplantation, etc.?
P: HCC relapsed after radical treatment
I: Surgical (hepatic resection, liver transplantation) treatment group
C: Non-surgical (RFA, TACE, sorafenib) treatment group
O: Survival rate
11. What is definition of TACE refractoriness and secondary treatment for these patients?
P: Patients who received TACE for HCC where hepatic resection/transplantation is impossible
I: Sorafenib, HAIC, TACE + sorafenib
C: Continue TACE or best supportive care
O: Survival rate
12.  What are molecular targeted agents and immunotherapy agents that can be primarily used on progressive HCC patients aside from 
sorafenib, and what are effects?
P: Progressive HCC patients
I: Molecular targeted agents and immunotherapy agents
C: Placebo or standard treatment (sorafenib)
O: Total survival period
13. What is effective secondary targeted agent for patients who failed treatment with sorafenib?
P: Patients who received sorafenib treatment for HCC but failed treatment
I: Regorafenib, nivolumab, cabozantinib
C: Conservative treatment
O: Survival rate
14. What are effects and safety of combined treatment of sorafenib and locoregional therapy for progressive HCC?
P: Progressive HCC patients
I: Combined treatment of sorafenib and locoregional therapy
C: Sorafenib alone
O: Survival rate and safety
Surgery
1. In what case is hepatic resection suitable for primary treatment of HCC?
P: HCC patients
I: Liver resection
C: Other treatment modalities
O: OS
2. Is hepatic resection suitable for HCC accompanied by portal hypertension or hyperbilirubinemia?
P: HCC patients with portal hypertension or hyperbilirubinemia
I: Liver resection
C: Other treatment modalities
O: OS, quality of life
3. Is hepatic resection useful for progressed HCC patients?
P: Advanced stage HCC patients
I: Liver resection
C: TACE, RT, sorafenib
O: DFS, OS
Supplementary Table 3. List of Clinical Questions (Continued)
4. In what case can laparoscopic hepatic resection be performed?
P: HCC patients
I: Laparoscopic liver resection
C: Conventional open liver resection
O: DFS, OS, complications, quality of life
5. In what case is liver transplantation suitable for primary treatment of HCC?
P: HCC patients
I: Liver transplantation
C: TACE, RT, sorafenib
O: OS
6. When is right time to perform bridging therapy for HCC prior to liver transplantation?
P: HCC patients within Milan criteria
I: Local ablation treatment or TACE
C: Conservative treatment
O: DFS, OS
7. Is liver transplantation useful after downstaging for progressive HCC patients?
P: Advanced stage HCC patients
I: Liver transplantation after downstaging
C: TACE, RT, sorafenib
O: DFS, OS
8. Is liver transplantation useful for HCC patients beyond Milan criteria without vascular invasion or extra-hepatic metastasis?
P: HCC patients above Milan criteria without vascular invasion or extra-hepatic metastasis
I: Liver transplantation
C: TACE, RT, Sorafenib
O: DFS, OS
9. Is salvage liver transplantation useful for HCC patients whose disease recurred after hepatic resection?
P: Recurred HCC patients after liver resection
I: Salvage liver transplantation
C: Liver resection, ablation therapy, TACE
O: DFS, OS
Radiology
1. What is suitable diagnostic test for patients suspected of having HCC?
P: Patients suspected of having HCC
I: Dynamic contrast-enhanced CT
C: Dynamic contrast-enhanced MRI, hepatocyte-specific contrast-enhanced MRI, contrast-enhanced sonography
O: Sensitivity, singularity
2. What is standard method of imaging diagnosis for patients suspected of having HCC?
P: Patients suspected of having HCC
I: Opinions about washout in arterial phase contrast enhancement/portal phase or delayed phase
C: Auxiliary image opinions
O: Sensitivity, singularity
3. Can HCC be diagnosed for nodules smaller than 1 cm on patients suspected of having HCC?
P: Patients suspected of having HCC
I: HCC smaller than 1 cm
C: HCC that is 1 cm or bigger
O: Sensitivity, singularity
4. Is standard method of imaging diagnosis same in initial diagnosis as in already diagnosed HCC patients?
P: HCC patients already diagnosed
I: Application of the same image diagnosis standard as initial diagnosis
C: Application of image diagnosis standard different from initial diagnosis
O: Accuracy of diagnosis
Supplementary Table 3. List of Clinical Questions (Continued)
5. Should radiation dose be considered when performing CT for HCC patients?
P: HCC patients
I: CT performed
C: CT not performed
O: Risk-benefit analysis
6. Are similar results expected from RFA as for surgical resection for HCC in terms of survival rate?
P: HCC patients
I: RFA
C: Hepatic resection
O: OS, PFS, TTP, complications
7. Is RFA superior to ethanol injection?
P: HCC patients
I: RFA
C: Ethanol
O: OS, PFS, TTP, complications
8. Is combined treatment of RFA and TACE superior to RFA alone for HCC?
P: HCC patients
I: RFA + TACE
C: RFA alone
O: OS, PFS, TTP, complications
9. Is cryoablation, microwave ablation useful locoregional therapy for HCC compared with RFA?
P: HCC patients
I: Cryoablation, microwave ablation
C: RFA, ethanol ablation
O: OS, PFS, TTP, complications
10. In what case is TACE suitable for adjuvant treatment of HCC?
P: HCC patients
I: TACE
C: Other treatment modalities
O: OS
11. Is performing TACE in advanced stage appropriate?
P: Advanced stage HCC patients
I: TACE
C: Conservative treatment, systemic chemotherapy
O: OS, quality of life
12. Is superselective TACE useful in TACE for HCC?
P: HCC patients
I: Selective TACE
C: Nonselective TACE
O: Tumor response, OS
13.  In what case is DEB-TACE adaptable? What benefits does it have compared with conventional TACE, and can it be recommended as 
standard therapy?
P: HCC patients
I: DEB-TACE
C: Conventional TACE
O: OS, PFS, TTP, complications, cost
14. Can TARE be considered as a standard therapy (that replaces TACE)?
P: HCC patients
I: TARE
C: TACE
O: OS, PFS, TTP, complications, cost
Supplementary Table 3. List of Clinical Questions (Continued)
15. Is TACE useful for treatment of HCC that has relapsed after hepatic resection?
P: Recurred HCC following hepatectomy
I: TACE
C: RFA, surgery
O: OS, PFS, TTP, complications
Radiation Oncology
1.  Can EBRT (radiotherapy including hypofractionated radiotherapy, stereotactic body radiotherapy, and particle radiotherapy) be 
performed for HCC in which hepatic resection or locoregional therapy is impossible?
P: HCC in which hepatic resection or locoregional therapy is impossible
I: EBRT including particle radiotherapy, hypofractionated radiotherapy, or stereotactic body radiotherapy)
C: TACE
O: Treatment result (OS, local control, progression free survival, toxicity)
2. In what case can EBRT be performed safely? What are indications?
P: HCC patients
I: EBRT
C: Dose-volumetric parameters
O: Radiation induced liver toxicity
3.  Is combined treatment with EBRT effective for HCC in which TACE is expected to show inadequate effect?
P: Locally advanced HCC patients
I: Combined treatment with TACE and EBRT
C: TACE alone
O: OS
4. Can EBRT be performed for HCC with macrovascular invasion?
P: HCC patients with macrovascular invasion
I: EBRT
C: Targeted agent (sorafenib)
O: OS
5.  Can EBRT be performed to alleviate pain caused by distant metastases of HCC or symptoms of metastatic cancer?
P: Patients with symptomatic HCC or metastatic disease
I: EBRT
C: Supportive care or systemic treatment
O: Symptom palliation/local control
6. Can EBRT perform role of down staging for surgical treatment in progressive HCC?
P: Locally advanced HCC patients
I: EBRT
C: Targeted agent (sorafenib)
O: Safety survival/OS
7.  Can EBRT be performed for HCC that has relapsed (refractory) after hepatic resection, RFA, ethanol injection, or TACE?
P: Recurrent or refractory HCC after locoregional treatment
I: EBRT
C: Repeated resection, RFA, ethanol injection, or TACE
O: Treatment result (OS, local control, progression free survival, toxicity)
CT = computed tomography, DAA = direct-acting antiviral, DEB = drug-eluting bead, DFS = disease-free survival, EBRT = external-beam 
radiation therapy, HAIC = hepatic arterial infusion chemotherapy, HCC = hepatocellular carcinoma, iRECIST = immunotherapy RECIST, 
mRECIST = modified RECIST, MRI = magnetic resonance imaging, mUICC, modified Union for International Cancer Control, OS = overall 
survival, PFS = progression-free survival, RECIST = Response Evaluation Criteria in Solid Tumors, RFA = radiofrequency ablation, TACE = 
transarterial chemoembolization, TARE = transarterial embolization, TTP = time-to-progression, WHO = World Health Organization
Supplementary Table 4. Process of Revision of 2018 KLCA-NCC Korea Practice Guidelines for Management of Hepatocellular 
Carcinoma
July 5, 2003: Established 2003 KLCSG-NCC Korea practice guidelines for management of HCC
June 27, 2009: Revised 2009 KLCSG-NCC Korea practice guidelines for management of HCC
June 14, 2014: Revised 2014 KLCSG-NCC Korea practice guidelines for management of HCC
May 2015: Published English version of 2014 guidelines in Gut and Liver and Korean Journal of Radiology
June 2017: Prepared NCC research fund (Principal Investigator Joong-Won Park, Project No. 1731510-1) after obtaining consent of NCC
  regarding proposal of revision of guidelines by KLCA (Chairman Joong-Won Park) and formed KPGRC (Supplementary Table 2)
June 26, 2017: Initial meeting of 2018 KPGRC (Seoul National University Hospital Cancer Research Institute 1F auditorium)
July to October 2017: Established first draft after several meetings in each department
October 28, 2017: First general meeting of KPGRC (Seoul National University Hospital Cancer Research Institute 1F auditorium)
November 2017: Each department held meetings about contents discussed at 1st general meeting and made revisions
November 25, 2017: Second general meeting of KPGRC (Seoul National University Hospital Cancer Research Institute 1F auditorium)
December 2017 to January 2018: Each department held meetings about contents discussed at 2nd general meeting and made revisions
January 27, 2018: Third general meeting of KPGRC (Seoul National University Hospital Cancer Research Institute 1F auditorium)
February to March 2018: Each department held meetings about contents discussed at 3rd general meeting, forwarded revised  
  draft online, and updated revision
March 22, 2018: First department head meeting (Gwanghwamun Dalgaebi)
April 26, 2018: Second department head meeting (Gwanghwamun Dalgaebi)
May 2018: Advisory board review
                Advisory board: Byeong In Choi (Chung-Ang University Radiology), Byeong Cheol Yoo (Konkuk University Internal Medicine), 
Gwang Hyeop Han (Yonsei University Internal Medicine), Seung Woon Baek (Sungkyunkwan University Internal Medicine), 
Gwan Soo Byeon (Korea University Internal Medicine), Won Jae Lee (Sungkyunkwan University Radiology), Tae Yoo Kim (Seoul 
National University Internal Medicine), Young Nyeon Park (Yonsei University Pathology), Shin Hwang (University of Ulsan 
College of Medicine Surgery)
May 31, 2018: Public meeting (Seoul National University Hospital Life Research Institute B1 auditorium)
June 2018: Third department head meeting online
June 2018: Final draft approved by board of directors of KLCA and NCC
June 15, 2018: Presented Korean version of 2018 KLCA-NCC Practice Guidelines for Management of HCC
  (Liver Week, Grand Hyatt Incheon)
KLCSG = Korean Liver Cancer Study Group, KPGRC = Korea Practice Guideline Revision Committee
